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Abstract 
While there is evidence of genetic susceptibility to autism, the degree of 
autistic individuals with specific genetic backgrounds is unknown. It is likely 
that other factors, such as environmental conditions, may play a role in this 
disease. Children with autism have been found to experience gastrointestinal 
(GI) problems (such as diarrhoea, constipation, abdominal pain and 
discomfort) more frequently and more severely than children from the general 
population.
In the present thesis, GI microbiota in children with autism were 
examined and compared with a matched control group. The results provide 
new information and a compelling picture of the GI microbiota of children with 
autism with GI symptomatology. Furthermore, a group of bacterial metabolites 
- biogenic amines - were examined in the faeces of children with autism and 
their matched sibling control group. 
The thesis results did not indicate any significant differences in the GI 
microbiota profile when compared with-in the group, regardless of the severity 
or type of GI dysfunction. Furthermore, no significant difference was found 
with neurotypical sibling control group. Similarly, there was no significant 
difference found in the concentration of the bacterial metabolite-biogenic 
amines when compared with a neurotypical sibling control group. Therefore, 
these observations suggest that GI dysfunction associated with autism might 
not be associated with the presence or absence of specific GI microbiota. The 
mechanisms that underlie GI dysfunction might involve factors other than GI 
microbiota like stress-induced changes in GI physiology. Animal studies 
suggest that perturbations of behaviour, such as stress, are associated with 
increased vulnerability to inflammatory stimuli in the GI tract which lead to GI 
dysfunction. Therefore, it might be possible that GI dysfunction associated 
with autism may have related to factor like early life stress.
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 Chapter 1 
Phenomenology of Autism Spectrum Disorder 
Introduction
Autism was first identified and proposed as a new psychiatric 
disorder by psychiatrist, Leo Kanner, in 1943 (Kanner, 1943) and was 
first included in the third edition of the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-III, APA 1980). Autism spectrum disorders 
(ASD) are a group of complex neurodevelopmental disorders with 
similar core features characterized by impairments in social interaction 
and communication, and restricted, repetitive and stereotyped patterns of 
behaviour. ASD include Autistic Disorder (typically referred to as 
autism) which is the most severe form, while other conditions along the 
spectrum include childhood disintegrative disorder, pervasive 
developmental disorder not otherwise specified (usually referred to as 
PDD-NOS) and Asperger’s Disorder.  ASD occur throughout the world in 
people of all ethnic and social backgrounds though it varies significantly 
in character and severity, with males being 4-10 times more likely to 
have an ASD than females (Baron-Cohen, 2002; Baron-Cohen et al., 
2001; Lord et al., 1982; Wing, 1981). The reason for the higher 
prevalence of autism in males is yet to be determined (Yeargin-Allsopp et 
al., 2004).
Experts generally agree that there are at least two types of ASD in 
terms of development: ‘classical autism’ is defined by abnormal 
cognitive development which is evident very early in infancy, and 
‘regressive autism’  which usually presents between 18 and 24 months of 
age following apparently normal development (Baron-Cohen, 2002). In 
cases of regressive autism, it is often reliably detected by the age of 42 
months and, in some cases, as early as 20 months (Wing, 1981).  
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 Common signs of ASD
The hallmark feature of ASD is impaired social interaction.  A 
child with ASD may appear to develop normally, then withdraw and 
become indifferent to social engagement after a certain age. Children 
with ASD may not respond to their names and often avoid eye contact 
with other people (Baron-Cohen et al., 2001). They have trouble 
interpreting what others are thinking or feeling because they may not 
understand social cues (or consider them salient), such as voice tone or 
facial expressions. These children also tend to avoid eye contact and, 
therefore, do not watch other people’s faces for clues about appropriate 
behaviour. Many children with ASD engage in repetitive movements 
such as rocking, twirling/spinning, staring and finger flapping or self-
abusive behaviours such as biting and head-banging. They are likely to 
start speaking later than other children (if at all) and may refer to 
themselves by name instead of “I” or “me”.  Children with ASD have 
difficulty playing and interacting with other children. Individuals with 
ASD  may also show unusual responses to sensations such as sound, 
touch, vision and smell (Lord et al., 1982). Auditory and visual 
processing problems are common (Dawson et al., 2000). Sensory 
problems vary from mild to severe with both over and under sensitivities.
Children with characteristics of ASD may also have other 
associated conditions such as Fragile X syndrome (which causes mental 
retardation), tuberous sclerosis, epileptic seizures, Tourette’s syndrome, 
learning disabilities and attention deficit hyperactivity disorder.  About 
20 to 30 % of children with ASD develop epilepsy by the time they reach 
adulthood (Canitano, 2007; Kanner, 1943). Apart from these conditions, 
some individuals with ASD possess unique abilities (savant behaviour) 
such as an accurate and detailed memory for information and facts, high 
visual recall and a superb ability to manipulate data for useful purposes. 
They may be able to focus for long periods of time on particular tasks or 
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 subjects and may be far more attentive to detail compared to people 
without ASD (Howlin et al., 2009). There is no medical test for diagnosis 
of ASD; rather, they may only be described as a cluster of specific 
behaviours. These behaviours are marked before the age of three years 
and continue, in the majority of cases, throughout the individual’s life.
Types of ASD
Currently, the term ASD is an umbrella description which refers to 
three different diagnoses according to DSM-IV-TR. 
1. Autistic disorder (classic autism):
The diagnosis of autistic disorder is given to individuals with
impairments in social interaction and communication. The condition is
often associated with restricted and repetitive interests, activities and 
behaviours. It is generally diagnosed prior to three years of age. 
2. Asperger’s disorder:
Individuals with Asperger’s disorder have difficulties with social 
interaction and communication, as well as restricted and repetitive 
interests, activities and behaviours. Individuals with Asperger’s disorder 
do not have a significant delay in early language acquisition or other 
cognitive abilities or self-help skills. Asperger’s disorder is often 
detected later than autistic disorder. 
3. Pervasive developmental disorder – not otherwise 
specified (PDD-NOS) (Atypical autism): 
The diagnosis of PDD-NOS is made when an individual has a 
marked social impairment but fails to meet full criteria for either autistic 
disorder or Asperger’s disorder. These individuals may also have 
communication impairments and/or restricted and repetitive interests, 
activities and behaviours.
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 Autism Diagnosis
There is no specific diagnostic test for ASD. Best-practice 
assessment utilises a multi-disciplinary approach. ASD varies widely in 
severity and symptoms and may go unrecognised for many years,
especially in children who have milder forms. Autism is currently 
diagnosed by the presence or absence of certain behaviours and 
developmental history. The criteria most widely used for diagnosis of 
autism in Australia  and North America come from the Diagnostic and 
Statistical Manual of Mental Disorders - fourth edition - text revision 
(DSM-IV-TR, APADSM-IV-TR, 2000). The DSM identifies three areas 
of functional impairment associated with a diagnosis of autism:
1. Impaired socialisation
2. Impaired communication
3. Restricted and repetitive patterns of behaviour, interests 
and activities
According to DSM-IV-TR, each of the three areas above contains 
four specific criteria, making a total of 12 criteria. For a diagnosis of 
autism, an individual must meet at least six of the 12 criteria (with at 
least two from the first domain and one each from the second and third 
domains). Therefore, individuals can meet a variety of different 
combinations of criteria and still receive a diagnosis of autism. Thus, 
individuals who have a diagnosis of autism may vary a great deal in their 
personality, abilities, behaviours and presentation.
The American Psychiatric Association (APA) is currently 
preparing the fifth edition of the DSM (DSM-V), which is due for 
publication in May 2013. In this edition, autism diagnostic criteria have 
been revised along with other mental disorders. It will merge various 
subtypes of autism into the singular diagnostic category of autism 
spectrum disorder with severity variants from mild to severe. Further it 
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 will eliminate the DSM-IV-TR categories of Asperger’s disorder and 
PDD-NOS and this will make a single category of autism spectrum 
disorder. For the ASD diagnosis, instead of three domains (impaired 
socialisation, impaired communication and restricted and repetitive 
behaviour) of diagnostic criteria stated in DSM-IV-TR, only two 
domains (social communication impairment and restricted 
interests/repetitive behaviours) will be used in the DSM (DSM-V). 
According to new proposed diagnosis criteria, individuals would be 
required to exhibit (1) three deficits in social interaction and 
communication and, (2) at least two repetitive behaviours. 
Prevalence of Autism
Autism was initially thought to be rare (and may indeed have been 
in the first few decades following Kanner’s seminal paper in 1943) but, 
during the 1990s, the number of persons reported to be receiving services 
for ASD increased substantially (Kadesjo et al., 1999; Sponheim et al., 
1998; Wing, 1993). According to  population-based studies conducted 
worldwide before 1985, the  prevalence of autism and related conditions 
was 0.4–0.5 per 1,000 children aged less than 18 years (Gillberg et al., 
1991; Lotter, 1966). Studies of ASD prevalence during the 1990s in the 
United States identified rates of 2.0–7.0 per 1,000 children (Fombonne, 
1996; Shattuck, 2006; Sturmey et al., 2001; Yeargin-Allsopp et al., 
2003). The US Centres for Disease Control (CDC) conducted surveys 
based on parent reports of diagnosed autism in their children. These 
studies indicated that 5.5–5.7 per 1,000 children aged 4–17 years 
received a diagnosis of autism during 2003–2004, approximately 1 child 
in every 150 (CDC, 2012; Charman, 2002; Rutter, 2005).  In 2007, 
according to the National Survey of Children's Health in the US, ASD 
prevalence was 110 per 10,000, an average of 1 child in every 100 
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 (Kogan et al., 2009). According to the recent CDC Autism and 
Developmental Disabilities Monitoring (ADDM) network, about 1 in 88 
children has been identified with an ASD and is almost 5 times more 
common among boys (1 in 54) than among girls (1 in 252). 
In Australia, there has been no national survey conducted to 
estimate the prevalence of ASD. However, surveys that have been carried 
out at the regional level (see Table 1) support the overseas estimates of 
the ASD prevalence.
Table 1. Autism prevalence studies in Australia.
Region Period of 
Study
Prevalence 
(per 10,000)
Reference
Australian Capital 
Territory
1989 9 Barker (2002)
1997 27
Western Australia 1999 159 Newschaffer et al. (2007)
2000 173
2001 204
New South Wales 2000 758 Treffert (1970)
Barwon Region, 
Geelong, Victoria
2002 39.2 Icasiano et al. (2004)
Epidemiological studies of ASD have provided evidence that the 
prevalence is increasing (Fombonne et al., 2001; Gillberg et al., 1991; 
Lotter, 1966; McCarthy et al., 1984; Treffert, 1970). Population-based 
prevalence surveys of autism have been conducted since the 1960s and 
summarized in recent reviews; these surveys have been used for 
evaluating changes in reported estimates over time (Fombonne, 2005; 
Kadesjo et al., 1999; Wing et al., 2002). Prevalence time tendencies for 
autistic disorder are available for longer time periods than for ASD as a 
group as PDD-NOS and Asperger’s disorder diagnoses were introduced 
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 in DSM-III-R and DSM-IV in 1987 and 1994, respectively. Based on the 
nature of the diagnostic criteria for different subgroups of ASD, it is 
possible that there were variations in the ways in which these were 
interpreted by different researchers (Newschaffer et al., 2007; Rutter, 
2005). However, differences in survey methodology, particularly changes 
in case definition and case identification over time, have made 
comparisons between surveys difficult to perform and interpret 
(Fombonne, 2005). 
Furthermore, the assessment process can also be affected by 
various other factors such as sample size, proportion of immigrants and 
methods of case-findings (Newschaffer et al., 2007). Increasing 
awareness of the existence of ASD among parents, professionals and the 
general public may also be one of the factors contributing to the reported 
increase in ASD prevalence (Newschaffer et al., 2007; Wing et al., 2002). 
ASD can be associated with other conditions including developmental 
disorders and/or physical disabilities. Therefore, it can cause diagnostic 
confusion if underlying symptoms are not recognised. Research is now 
being undertaken on the association of autism with a range of identifiable 
abnormalities including Fragile X (Turk et al., 1997), Turner’s syndrome 
(Creswell et al., 1999), epilepsy and Down’s syndrome (Howlin et al., 
1995). 
It has been observed that because of the stereotyped view of 
children with the associated disorder, the presence of autism has often not 
been diagnosed (Howlin et al., 1995). Genetic factors alone are less 
likely to account for a real increase in incidence that appears to have 
occurred so rapidly and continuously year by year (Hertz-Picciotto et al., 
2006; Persico et al., 2006). If there is a real increase that is continuous, 
environmental factors are likely implicated. 
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 Many hypotheses and theories have been made concerning 
possible cause, including environmental pollutants, use of antibiotics in 
early stages of life, gastrointestinal dysbiosis, constituents of diets, 
vaccines and exposure to heavy metals and allergies, but none  has yet 
been scientifically validated (Hertz-Picciotto et al., 2006). The 
assessment of gastrointestinal (GI) microbiota (one of the environmental 
factors which may contribute to ASD symptomatology) was the main 
focus of this thesis. Hypotheses relating to the possible involvement of 
GI microbiota in ASD are  discussed in the next chapter. 
All or some of the factors discussed above may have contributed 
to the observed increase in the prevalence rate of ASD. However, there is 
no certainty as to how much of the increase they may explain. It remains 
an open debate whether there is a genuine increase in the number of 
children with ASD or if this is due to the changes in the diagnostic 
criteria and public awareness of the condition (Newschaffer et al., 2007; 
Wing et al., 2002). 
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 Chapter 2 
The pathophysiology of autism and gastrointestinal factors 
For more than three decades after autism was first described, it 
was believed to be a psychogenic disorder. However, according to new 
research, the high incidence of mental deficiency and epileptic seizures 
point to biological determinants. Many studies have reported structural 
abnormalities in various regions of the brain (Brambilla et al., 2003; 
Sparks et al., 2002). Genetic influences have also been noted; there are 
high concordance rates in siblings of children with autism, as well as in 
monozygotic twins (Hallmayer et al., 2011; Rosenberg et al., 2009). 
Hence, it has now become generally accepted that autism has a biological 
basis. Nevertheless, the etiology of autism is complex and the underlying 
pathophysiological mechanisms are unknown in most cases. A number of 
causes have been proposed, including various medical conditions (Fragile 
X syndrome, phenylketonuria and Down’s Syndrome), perinatal insult, 
autoimmune mechanism and genetic susceptibility to environmental 
factors, gastrointestinal dysfunctions and dysbiosis/infectious agents.
Family and twin studies have provided evidence that autism is a 
genetic neuropsychiatric disorder, with concordance rates of 60–91% in 
monozygotic twins depending on whether a narrow or broad phenotype is 
considered for the diagnosis. This is very much in contrast with dizygotic 
twins,  with 0–10%  concordance depending on a narrow or broader 
phenotypic definition (Folstein et al., 2001; Veenstra-Vander Weele et al., 
2004). 
However, in recent years, different levels of complexity have 
emerged in relation to autism and genetics, namely a high degree of 
genetic heterogeneity (different contributing genes in different patients), 
a polygenic or oligogenic inheritance mode in most cases (i.e. many 
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 susceptibility gene variants at different loci are required for an individual 
to develop the disease) and the presence of significant gene–gene and 
gene–environment interactions (Abrahams et al., 2008). By identifying 
genetic markers inherited with autism in family studies, numerous 
candidate genes have been located, most of which encode proteins 
involved in neural development and function (Persico et al., 2006). 
However, for most of the candidate genes, the actual mutations that 
increase the risk for autism have not been identified. Typically, autism 
cannot be traced to a Mendelian inheritance or to single chromosome 
abnormality such as Fragile X syndrome (Cohen et al., 2005; Muller, 
2007). 
According to a recent study, around 103 genes and 44 genomic 
loci have been reported in ASD (Betancur, 2011) with significant overlap 
with other conditions such as intellectual disability, epilepsy, 
schizophrenia and attention deficit hyperactivity disorder (ADHD). 
These findings therefore suggest that ASD is not a single-gene disorder 
but rather a complex disorder resulting from coinciding genetic variations 
in multiple genes (El-Fishawy et al., 2010). Moreover, it supposed to 
have complex interactions between genetic, epigenetic and 
environmental factors. Genetic contributors to autism may be associated 
with a broader range of mechanisms beyond those directly associating 
with the central nervous system. In particular, these mechanisms may 
confer increased vulnerability to environmental factors and they involve 
other organ systems such as the gastrointestinal or immune systems, two 
systems which are on the frontlines of the individual’s interaction with 
the environment.
Very few research studies on gastrointestinal symptoms in ASD 
were reported prior to the 1990s (Goodwin et al., 1971; Walker-Smith et 
al., 1972) and little attention was given to these findings until last decade 
when routine gastrointestinal evaluation of children with ASD revealed a 
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 high prevalence of gastrointestinal symptoms, histologic changes in 
digestive tract, gastrointestinal dysfunction and abnormal gut microbiota 
compared to control children. A study by Wakefield and colleagues 
(2000) reported the first systematic evaluation of children with autism 
and GI symptoms. On endoscopy of the lower GI tract, 93% of the 
children evaluated had ileal lymphonodular hyperplasia (LNH) and 30% 
had colonic LNH. Chronic colitis (inflammation) was also present in 
most of the patients. These children had one or more of the following 
symptoms at the time of their evaluation: abdominal pain, constipation, 
diarrhoea (or alternating constipation and diarrhoea) and bloating.  A 
similar study (Horvath et al., 1999b) performed endoscopic evaluations 
of the upper GI tract in symptomatic children with autism and reported 
high prevalence of gastrointestinal abnormalities such as inflammation, 
decreased intestinal carbohydrate digestive enzyme activity, and most 
individuals experienced symptoms of abdominal pain, chronic diarrhoea, 
gaseousness/bloating and unexplained irritability. The high prevalence of 
GI symptoms provide evidence for an association between autism and  
GI symptoms and have increased clinician’s and researcher’s awareness 
of the chronic GI problems that can occur in children with an ASD. 
In the late 1990s, researchers began studying GI microbiota as a 
potential factor in the GI dysfunction associated with autism and studies 
were designed to examine faeces of children with autism for the presence 
of various microorganisms. Researchers have used a variety of 
techniques to study the GI microbial profile ranging from conventional 
culture methods to extensive molecular biology techniques (Bolte, 1998; 
Finegold et al., 2002; Song et al., 2004). Many hypotheses have been 
proposed that involve GI microbiota in autism including: the presence of 
Clostridium spp. (Bolte, 1998; Finegold, 2008); the use of high doses of 
antibiotics in the early stage of life (Adams et al., 2007; Fallon, 2005); 
food intolerance (Gorrindo et al., 2012); colonisation by pathogenic 
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 bacteria (Finegold et al., 2002); and, Candida infection (Shaw et al., 
1995). 
However, to date, researchers have not been able to definitively 
demonstrate a link between GI microbiota and autism. The possible role 
of GI microbiota in autism is fundamental to this thesis. Therefore, the 
associated research program was designed to explore GI microbiota in 
children with autism and determine whether it differs from that of a non-
clinical healthy control group and if there is any evidence of an 
association between GI microbiota and the clinical severity of ASD. 
Food intolerance in the autistic population, particularly for wheat 
and cow’s milk, is very common (Goodwin et al., 1971; Gurney et al., 
2006). Based on this observation, other GI conditions like ‘leaky gut 
syndrome’/intestinal epithelial barrier dysfunction has been hypothesised 
to co-occur with autism symptoms (Rimland et al., 1996; White, 2003). 
Two different studies have reported increased intestinal permeability at a 
high frequency (43% and 75%) in ASD children with GI symptoms 
(D'Eufemia et al., 1996; Horvath et al., 2000). However, a study with 14 
children with autism having current or previous GI complaints found no 
evidence of altered intestinal permeability (Robertson et al., 2008). 
Excessive levels of incompletely metabolised peptides from 
certain substances found in common foods, particularly the casein in 
cow's milk and the gluten and gliadin in wheat and other cereal grains, 
can pass through the intestine and leak into the bloodstream. This can 
induce immunogenic responses. It is thought that due to deficient enzyme 
activity in the lumen of the small intestine, wheat (gluten) and milk 
(casein) proteins are incompletely broken down (Kidd, 2002) into short 
neuroactive peptides such as β-casomorphin (Tyr-Pro-Phe-Pro-Gly-Pro-
Ile) generated from casein and gliadinomorphin (Tyr-Pro-Gln-Pro-Gln-
Pro-Phe) generated from gluten (Reichelt et al., 1994). These products 
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 are potent psychosis-inducing factors (Lindstrom et al., 1984) which 
enter into the bloodstream and cross the blood-brain barrier to exert an 
opioid-like effect in the brain (Reichelt et al., 1994). 
In a study by Reichelt and Knivsberg  (2003), abnormal opioid 
peptide concentrations were reported in urine samples from autistic 
children. Based on analysis of urine samples, dietary intervention 
involving gluten-and/or casein-free food has been proposed to be 
effective in some of the behavioural symptoms of autism. However, this 
diet has not been scientifically established to produce improvements in 
ASD symptomatology. Following dietary restriction of gluten and/or 
casein, a number of studies reported that the urine peptide profile 
normalized in autistic children and significant reductions of autistic 
behaviour, epileptic fits and aggression were achieved, with an increased 
level of attention, and acquisition of language and social skills 
(Knivsberg et al., 1998; Reichelt et al., 1990; Reichelt et al., 1991). 
Conversely, a smaller number of studies found the reversal of urine 
peptide profile and behaviours that were not significantly different to 
control groups (Elder et al., 2006; Sponheim, 1991; Whiteley et al., 
1999). However, these studies were not randomised trials and the 
behavioural assessments were not carried out by evaluators blind to the 
intervention. In a placebo-controlled trial (Johnson et al., 2011), children 
with ASD aged between 3 and 5 years were randomly allocated to a 
gluten-casein free diet (n = 8) or a low-sugar diet (n = 14) for a 3 month 
period using an open-label design. There were no statistically significant 
differences observed between groups when compared across a range of 
behavioural and developmental outcomes. Currently, there is little 
empirical evidence from randomised control trials to support the use of 
gluten and/or casein free diets as an effective intervention for children 
with ASD (Whitehouse, 2013).
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 Several studies have taken a different approach by focusing on 
immunological responses to dietary proteins. A study by Jyonouchi et al. 
(2002), found that peripheral blood mononuclear cells from children with 
ASD responded to gliadin, cow’s milk protein and soy by producing 
higher levels of inflammatory cytokines in comparison to typically 
developing children. Studies looking at mucosal immune responses in 
children with ASD who have GI symptoms have shown increased 
infiltration of eosinophil, T-cells and monocytes in the gut mucosa and 
increased numbers of paneth cells, compared with non-inflamed control 
subjects or compared with children with celiac disease and inflammatory 
bowel disease (Kolevzon et al., 2007; Rellini et al., 2004; Sullivan, 
2008).
Numerous research studies point to the presence of immune 
dysfunction in some children with ASD, which is consistent with 
autoimmunity (Croen et al., 2005; Goines et al., 2010). Most autoimmune 
diseases result from a complex interaction between genetic and 
environmental factors. Various genes are thought to be associated with an 
increased risk of developing certain autoimmune diseases. The human 
leukocyte antigen (HLA) genes are among the strongest predictors of risk 
for autoimmune conditions (Wing et al., 2002). Different HLA 
haplotypes are also associated with schizophrenia and ASD (DeSoto, 
2009; Karr et al., 2007; Krakowiak et al., 2012).
Though it is not known whether immune activation plays an 
initiating or maintaining role in the pathology of ASD, immune activation 
leading to inflammation can have serious damaging effects and could 
lead to tissue damage. Increased immune activation is associated with a 
number of neurodegenerative disorders and is speculated to play a role in 
psychiatric disorders such as depression, schizophrenia, obsessive 
compulsive disorder, bipolar disorder as well as ASD (Ashwood et al., 
2011; Fombonne et al., 2001; Howlin et al., 1995). Elevated levels of 
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 inflammatory cytokines in the CNS could reflect an inflammatory 
process that might contribute to abnormal neurodevelopment as seen in 
ASD.
The presence of antibodies against brain and CNS tissue has been 
repeatedly reported in children with ASD (Knivsberg et al., 2002; 
Roberts et al., 2007). These antibodies have various targets, including 
neuronal proteins, neurotransmitter receptors and nuclear material (Kidd, 
2002; Reichelt et al., 1994). However, it is not clear whether these 
autoantibodies have direct pathogenic relevance or are instead secondary 
to previous cellular damage or inflammatory reactions. Although some 
investigators have analysed whether antibodies are directed at specific 
targets, such as myelin basic protein or glial fibrillary acidic protein, no 
clear associations between ASD and specific antibodies have been 
replicated across studies to date. This lack of specificity may suggest that 
the antibodies are generated as a consequence of some previous 
undiscriminating damage that involves CNS targets, leading to the 
generation of a diverse array of antibody specificities, as seen in ASD. 
Alternatively, the presence of these autoantibodies could reveal a group 
of ASD individuals who are more prone to immune dysfunction. Notably, 
antibodies directed at gut epithelium have also been described in ASD 
children (Careaga et al., 2010). However, no link between gut and brain 
antibodies has been established.
A theory linking vaccines and autism has also been proposed with 
many controversial findings across the research literature. In two separate 
reports by Fudenburg (1996) and Gupta (1996), a close sequential 
association between the administration of the MMR vaccine and the 
onset of autistic symptoms in patients was noted. Kawashima et al. 
(2000) reported genomic RNA of the measles virus vaccine strain in 
peripheral mononuclear cells in three out of nine autistic patients and one 
of three patients with ulcerative colitis, while all controls were negative.
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 The most controversial autism research article of the last decade 
by Wakefield et al. (1998) (retracted in 2010 because of scientific fraud 
and ethical violations) noted intestinal pathology, namely the 
hyperplastic lymph nodes in the ileum and colon, suggesting that the 
immune system of the gut has been seriously challenged in the autistic 
children. Although this group did not draw a conclusion as to the cause of 
the pathology, they noted based on parental reports that the children had 
received the trivalent measles-mumps-rubella (MMR) vaccine before 
undergoing behavioural regression. The research by Wakefield et al. has 
drawn scientist’s and clinician’s attention toward the potential association 
between vaccines and autism and started a series of investigations in this 
field. 
MMR vaccine has an enormous beneficial effect upon public 
health and is highly efficacious in limiting childhood measles, mumps,
and rubella infections. Therefore, the studies suggesting that the MMR 
vaccine may be an etiological factor in autism created very high public 
health concern. Hence, several epidemiological studies of different 
populations have been carried out to examine the relation between 
vaccinations and the prevalence of autism. After carefully reviewing the 
case history of 473 autistic children in London (UK) over a 20-year 
period starting from 1979, Taylor et al. (1999) found no significant 
variation in the proportion of children with developmental regression or 
bowel problems before and after introduction of the MMR vaccine. 
Similarly, independent studies by Dales et al. (2001), Miller et al. (1997)  
and Fombonne et al. (2001) have failed to find any significant correlation 
between the distinct syndrome of MMR-induced autism or of autistic 
enterocolitis.
There are considerable controversies surrounding the published 
findings as well as many of the related issues discussed within this thesis. 
Therefore, it is essential to examine the pathophysiology of autism and 
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 extend research to evaluate the supposed theories and hypotheses as a 
tool in the clinical diagnosis of autism. All potential links between GI 
pathophysiology and autistic symptoms must be given cautious and 
rigorous examination. Even if the GI pathology is unrelated to the 
etiology of autism or its unique symptomatology, the findings appear to 
verify what parents and physicians have long suspected in that many 
autistic children have abnormal GI function. As one of the suspected GI 
dysfunction theories relates to abnormal GI microbiota in children with 
autism, the focus of this research was to empirically test this hypothesis.
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 Chapter 3 
Gastrointestinal microbiology in autistic spectrum disorder: A review
In 1971, researchers for the first time reported  a co-incidence of 
autism with celiac disease and reported elevated rates of GI dysfunction 
in autistic individuals (Goodwin et al., 1971). This promoted a series of 
related investigations of biological abnormalities in autism. The high 
rates of GI dysfunction in individuals with ASD have been reported in 
several studies with symptoms including one or more of: abdominal pain, 
constipation, diarrhoea and alternating constipation. (Ashwood et al., 
2011; Gorrindo et al., 2012; Horvath et al., 1999b). 
 GI dysfunction associated with autism has been hypothesised to 
be related to the colonization of harmful bacteria in the intestinal tract 
(Bolte, 1998). This was supported by other theories including: late-onset 
autism preceded by the use of broad-spectrum antibiotics, and the use of 
anti- and/or pre/pro-biotics to improve GI symptoms as well as autistic 
symptoms (Sandler et al., 2000; Tuohy et al., 2003; Weber et al., 2007). 
Some fungal species, in particular Candida, have the ability to establish 
on gastrointestinal mucosa and induce intestinal permeability which 
allows the passage of undigested molecules through the intestinal wall 
and creates a series of reactions often observed in individuals with autism 
and allergy symptoms. 
It also has been hypothesised that viral infection early in life and 
during pregnancy may trigger ASD (Rosen et al., 2007) but the 
mechanism is not known. These observations have stimulated a series of 
investigations of the involvement of microorganisms in the 
pathophysiology of GI dysfunction associated with autism. However, 
there is inconsistency in the findings of different studies regarding the 
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 specific group(s) of microorganisms potentially involved with ASD. 
Given the mixed findings of previous studies, it appeared that mere 
replication of this research would be unlikely to add substantial new 
information of the role of GI microbiology in autism.
Therefore, the following paper (Gondalia et al., 2010b) sought to 
comprehensively review the possible involvement of GI microbiota, 
including bacteria, viruses and fungi, in autism. Furthermore, the paper 
sought to contribute to the literature by reviewing the current hypotheses, 
outlining previous research and providing discussion of fresh directions 
or perspectives which researchers in this field could consider to advance 
the understanding of the possible role of GI microbiota and associated 
factors in ASD.
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 Chapter 4 
Faecal microbiota of individuals with autism spectrum disorder 
The paper presented in the previous chapter (Gondalia et al., 
2010b) suggested that research into GI microbiology and autism to date 
has provided mixed findings and often contradictory conclusions. 
Specifically, when trying to find an association between autism and GI 
microbiota, it is difficult to make a hypothesis about whether GI 
microbiota are related with the onset of autism or whether they are 
secondary to the disease processes that cause autism or subsequent to 
neurobiological dysfunctions. Previous research has suggested that 
certain bacteria such as Clostridium spp. are associated with the onset of 
autism (Finegold, 2008; Finegold et al., 2002). It has also been observed 
that the GI tracts of children with autism have lower counts of ‘good’ 
bacteria (such as Lactobacillus, Bifidobacterium) and are colonised with 
more harmful bacteria (such as clostridia) compared to neurotypically 
developing children (Finegold, 2008; Finegold et al., 2010; Finegold et 
al., 2002; Song et al., 2004). 
GI microbial ecosystem is very diverse and complex to study in 
the laboratory. The GI microbiota is highly influenced by the surrounding 
environment, personal hygiene conditions and dietary factors. It can be 
altered by treatment with antibiotics, probiotics and prebiotics. The GI 
microbial ecosystem plays an important role in an individual’s health. 
Any disruption of this system may lead to disease conditions. Recent 
research in this field has indicated the involvement of bacterial infection 
and disruption of the normal microbial profile in the GI tract of patients 
with Crohn’s disease (Sartor, 2006) and irritable bowel syndrome 
(Posserud et al., 2007; Pyleris et al., 2012). Research has suggested that 
the GI microbiota is greatly affected by anxiety and stress-like conditions 
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 (Ait-Belgnaoui et al., 2012; Lutgendorff et al., 2008). Therefore, it is 
possible that a condition like autism may affect the resident GI 
microbiota rather than vice versa. Of course, the relationship could be bi-
directional (at least in a population of ASD patients). The association of 
autism and GI microbiota seems apparent, although we are unable to 
consistently identify, even quantify, their detailed nature or mode of 
action as it relates to the increase or maintenance of autism. Furthermore, 
determining the role of GI microbiota in the pathophysiology of autism 
and identifying all microbial entities, including viruses and fungi, are 
challenging and require rigorous research. Thus, this thesis has focused 
on the role of GI bacteria in relation to ASD.
The following study was designed as a pilot study on the basis of 
the aforementioned research literature that suggests gastrointestinal 
microbiota may play a role in the pathophysiology of ASD. This was the 
first study of its kind conducted in Australia. The aim of this study was to 
determine if a relationship exists between ASD severity and GI microbial 
populations. This was done by examining whether any particular 
bacterial group was consistently present or absent (or in higher or lower 
numbers) in autistic children of various clinical severities. This study also 
attempted to determine whether the microbial profile of children with 
autism differed from a laboratory reference range.  
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Abstract 
Many children with autism spectrum disorders (ASDs) 
suffer from gastrointestinal problems such as diarrhoea, 
constipation and abdominal pain. Such symptoms may 
be due to a disruption of the indigenous gut microbiota 
promoting the overgrowth of potentially pathogenic 
microorganisms. These observations have stimulated 
investigations into possible abnormalities of intestinal 
microbiota in autistic patients. The purpose of the present 
study was to determine if a relationship exists between 
ASD severity (mild – severe) and gastrointestinal (GI) 
microbial populations. The faecal microbiota of 22 male 
and 6 female participants with ASDs (aged 2-14  years) 
were analyzed by standard microbial culture methods 
and compared within-group (based on ASD severity) and 
with a standard laboratory reference range. Comparisons 
between children with mild ASD and those with 
moderate to severe ASD, as well as comparisons to a 
neurotypical control group previously reported, revealed 
that no significant differences appear to exist in the 
composition of the gut microbiota. Nevertheless, 
examination of each individual’s gut microbial 
composition showed 10 cases of unusual findings which
means 1 out of 3 cases have unusual microbiota. Our
data do not support consistent GI microbial abnormalities 
in ASD children, but the findings do suggest that 
aberrations may be found in a minority of ASD children. 
Further studies are required to determine the possible 
association between the microbiota and gastrointestinal 
dysfunctions in a subset of children with both ASD and 
gastrointestinal problems.
Keywords: Microbiota; ASD; gastrointestinal tract; 
bacteria
Introduction
Autism spectrum disorders (ASD) are behaviorally 
defined developmental disorders (including autistic and 
Asperger’s disorder) with a wide range of behaviours. 
Although the etiology of ASD is unknown, data suggest 
that autism may have multiple etiologies with both 
genetic and environmental contributions (Herbert, 
2010). This diverse etiology may explain the spectrum 
of observed behaviours seen in affected individuals. 
Nevertheless, recent studies have suggested 
gastrointestinal (GI) disorders and associated symptoms 
are commonly reported in individuals with ASD, but 
key issues such as the prevalence and best treatment of 
these conditions are incompletely understood (Buie, 
Campbell et al., 2010; Buie, Fuchs et al., 2010; 
Galiatsatos, Gologan, & Lamoureux, 2009; Gondalia, 
Palombo, Knowles, & Austin, 2010). The clinical 
picture of GI disturbance includes constipation,
diarrhoea, foul-smelling stools, gaseousness, abdominal 
bloating, signs of abdominal discomfort, and decreased 
intestinal carbohydrate digestive enzyme activity 
(Horvath, Papadimitriou, Rabsztyn, Drachenberg, & 
Tildon, 1999). Nevertheless, the incidence and nature of 
GI symptoms in those with ASD remains somewhat 
uncertain and, even, controversial (Ibrahim, Voigt, 
Katusic, Weaver, & Barbaresi, 2009; Kuddo & Nelson, 
2003; Molloy & Manning-Courtney, 2003).
Reasons to consider that microorganisms may be 
involved in autism include the following; 
gastrointestinal symptoms are common at ASD onset 
and often persist, antimicrobials (e.g., oral vancomycin) 
may lead to a clear-cut response and relapse may occur 
when the vancomycin is discontinued, and some 
patients have responded to several courses of 
vancomycin and relapsed each time it was discontinued.
Vancomycin has proven effective in reducing autistic 
symptomatology and is known to be highly effective 
against Gram-positive organisms. When given orally, 
vancomycin is poorly absorbed by the gut, so any effect 
seen with its use is likely due to its action on intestinal 
bacteria (Finegold, 2008; Sandler et al., 2000).
One hypothesis is that the toxins produced by 
microorganisms may play an important role in the cause 
of ASD, in particular, lipopolysaccharides (LPS), the 
bacterial toxins from Gram-negative bacteria (Gondalia 
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et al., 2010). LPS induces a depressive syndrome, 
characterized by anhedonia, anorexia, body weight loss, 
and reduced locomotor, exploratory, and social 
behaviours (Marvel, Chen, Badr, Gaykema, & Goehler, 
2004; Singal, Tirkey, Pilkhwal, & Chopra, 2006). LPS 
toxicity works synergistically with mercury and other 
heavy metal poisonings to expand damage (Rumbeiha, 
Fitzgerald, Braselton, Roth, & Kaneene, 2000). 
Interestingly, mercury is arguably a suspect as an 
environmental trigger in some etiological theories of 
ASD (Austin, 2008; Bernard, Enayati, Redwood, 
Roger, & Binstock, 2001; Palmer, Blanchard, Stein, 
Mandell, & Miller, 2006; Palmer, Blanchard, & Wood, 
2009).
The microbiological ecosystem of the gut is complex 
and not completely understood, but appears to be of key 
importance in health and disease (Gibson & Roberfroid, 
1995) and is often conceptualized as an essential 
"organ" in providing nourishment, regulating epithelial 
development, instructing innate immunity and a broad 
range of other activities. Intestinal bacteria secrete both 
detrimental and beneficial compounds and overgrowth 
of certain species of bacteria or other changes to the 
normal intestinal microbiota have been reported with 
ASD (Finegold et al., 2002; Yap et al., 2010). The 
treatment of GI dysfunction in ASD with anti- or 
probiotics has been proposed as a way to regulate 
intestinal microbiota and subsequently improve 
symptom severity in ASD (Sandler et al., 2000; Tuohy, 
Probert, Smejkal, & Gibson, 2003). The variable results
reported are not surprising given the lack of consistent 
evidence as to the specific microbial adjustment that is 
desirable. While many studies have compared the faecal 
microbiota of individuals with ASD to controls 
(Finegold et al., 2002; Parracho, Bingham, Gibson, & 
McCartney, 2005; Song, Liu, & Finegold, 2004), only 
one has examined the relationship between faecal 
microbiology and ASD severity (Finegold et al., 2010).
The purpose of the present study was, therefore, to 
determine if a relationship exists between ASD severity 
(mild – severe) and GI microbial populations. Such an 
association would be consistent with a dose-response 
relationship whereby GI microflora aberrations are 
considered to play a role in the aetiology of the disorder 
or, alternatively at least, a mechanistic role related to 
symptom severity.
Method 
Participants 
Twenty-eight individuals aged 2-14 years (M = 4.8,
SD = 3.3; 22 male and 6 female) with ASD participated
in this study. None of the participants were taking 
antibiotics within 14 days prior to the sampling. Dietary 
intake was not controlled and so this likely varied 
across individuals. The participants were recruited from 
consecutive patients presenting to the private 
psychology practice of the fourth author. The study was 
approved by the Human Research Ethics Committee of 
Swinburne University of Technology, and informed 
consent was given by parents on behalf of their children 
who participated in the study.
Faecal sampling and analysis
Faecal microbial analysis by standard microbial 
culture methods was carried out by a commercial 
laboratory, Bioscreen Medical 
(www.bioscreenmedical.com). Participants were 
provided with a sample collection kit containing a
specimen container (lid with two holes), an air-locked 
plastic bag, two gel freezer packs and an AnaeroGen 
Compact foil sachet (Oxoid, UK) to create anaerobic 
conditions inside the plastic bag. 
Faecal samples were collected in specimen containers 
with a scoop attached to the lid. Participants were 
instructed to collect enough faeces to fill at least 1/3 of 
the scoop with faeces from used toilet paper. 
Participants were instructed to screw the lid on firmly, 
place the container in the plastic bag along with an 
opened AnaeroGen Compact foil sachet and seal the 
bag to make it airtight. For transport to the laboratory,
samples were sealed in a polystyrene box together with 
two freezer packs. 
Statistical methods 
Faecal microbial analysis was carried out to identify 
the presence and quantities of bacteria (aerobes and 
anaerobes), and the yeast, Candida. Analysis of 
variance was used to examine difference between mild 
and severe ASD groups. Data analysis was also carried 
out between the ASD groups as a whole and the 
commercial laboratory reference ranges. Various 
groups of organisms were also analysed for possible 
significant associations and data from this study were 
compared with that from published control group data 
(Finegold, Flora, Attebery, & Sutter, 1975) as well as to 
the laboratory reference ranges. Data were analyzed 
using the Statistical Package for Social Sciences 
(SPSS). 
Results & Discussion 
Participants were divided into two groups: those with 
moderate to severe ASD (n = 16) and those with mild 
ASD (n = 12) (Table 1). The severity category was 
based on CARS (Childhood Autism Rating Scale) 
assessments conducted by registered psychiatrists or 
psychologists and the child’s score reported by parents’ 
of participants. Scores of less than 37 are considered 
mild and those at or above 37 are considered moderate 
– severe (Rellini, Tortolani, Trillo, Carbone, & 
Montecchi, 2004). Details on the specific bacteria 
recovered with ranges and converted mean counts are 
given in Table 2. These counts represent a conversion 
from the means obtained after log transformation of the 
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data values. The log transformation was used because 
of extremely skewed distributions of some organisms, 
which reflected relatively small sample numbers. All 
counts are based on weight of dry stool.  
Analyses of variance revealed no significant 
differences between the two ASD severity groups on 
mean levels for any of the analytes (see Table 1).
Furthermore, no relationships were evident between the 
levels of any bacterial populations examined across age 
and gender. Inspection of each individual case revealed 
some aberrant results, but not in a consistent or 
common enough pattern to significantly affect the mean 
group levels. Ten ASD children appeared to show more 
variation in microbial profile than the other 18 ASD 
children (see Table 3). Given the lack of associations 
between GI microflora population levels and autism 
severity we decided to compare our total sample means 
with the normal laboratory reference ranges as well as 
means reported for neurotypical individuals in a 
previously published study (Finegold et al., 1975).
Table 1 
Mean values of faecal microbiota examined for 
different groups (mild vs. moderate-severe) of ASD 
individuals 
Mild 
ASD 
group
(n = 12)
Moderate to 
severe ASD 
group
(n = 16)
P-value
Total bacterial count 10.26 10.36 .62
Total aerobe count 7.31 7.37 .83
Total anaerobe count 10.26 10.35 .64
Candida 2.48 3.98 .07
Escherichia coli 6.44 6.69 .55
Enterococcus spp. 6.79 6.51 .58
Staphylococcus spp. 5.62 5.63 .98
Streptococcus spp. 6.71 6.73 .96
Bifidobacterium spp. 9.14 9.38 .52
Clostridium spp. 7.24 7.47 .79
Anecdotal reports by parents and several recent 
reports have provided evidence that ASD children 
suffer from disturbed GI tract function (Buie, Campbell 
et al., 2010; Buie, Fuchs et al., 2010). Nevertheless, 
comprehensive assessments of GI abnormalities in ASD 
children are not widely or routinely performed. In the 
present study, comparisons between children with mild 
ASD and those with moderate to severe ASD (Table 1),
as well as comparisons to a neurotypical control group 
(Table 2), revealed that significant differences did not 
appear to exist in the composition of the gut microbiota. 
However, examination of each individual’s gut 
microbial composition showed occasional cases of 
unusual findings. For example, in four ASD 
participants, we found low numbers of total bacterial 
and total aerobes (patients 1, 2, 7 and 9). Escherichia 
coli levels were lower than the normal range in ASD 
patients 2, 4 and 5, while other aerobic bacteria 
(Citrobacter spp., Enterobacter spp., Staphylococcus 
and Streptococcus spp.) were higher than the normal 
range in two ASD patients and Bifidobacterum were 
significantly higher than the normal range. Clostridium
spp was higher in patient 8 (see Table 3).
There are several important limitations to this study
that should be acknowledged. One is the small sample 
size, and the resultant limitations to generalisability of 
the findings and statistical power. Also, we did not 
utilise a control group but, rather, compared our clinical 
data to previously published data and laboratory 
reference ranges for normal control populations. A 
further limitation was our single time-point sampling 
which does not allow for determining stability of 
microbial populations over time. Finally, we did not 
control for dietary differences amongst our participants. 
Obviously, it would be ideal to experimentally 
manipulate dietary intake to remove its influence on GI 
microbiology. 
The kind of individual aberrations found in our 
sample are consistent with the current consensus that GI 
dysfunction does occur more frequently in ASD than 
non-ASD children (Buie, Campbell et al., 2010), but 
possibly only in a minority of individuals It is critical, 
therefore, for future research to attempt to identify this 
minority a priori in order to conduct more advanced 
testing beyond group mean comparisons which our 
study show may dilute (at a group level) any aberrations 
apparent in the minority of children. Furthermore, 
future researchers should cast a wider net in their search 
for microbial correlates in ASD. All studies conducted 
to date have examined only a fraction of the microbial 
species known to inhabit the gut, both pathogenic and 
commensal. Additionally, microbial species beyond 
bacteria should be examined, including viruses, fungi 
and protozoa. If microbial correlates to the GI 
dysfunction seen in ASD can be identified, promising 
opportunities for influencing the clinical course of the 
GI disturbance through appropriate intervention may be 
developed, such as pro- or antibiotic therapy or dietary 
intervention.  
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Table 2 
Comparison of bacterial counts between individuals with an ASD, control group and laboratory reference range 
Lab ref
(n = 177)a
Total ASD
(n = 28)
Controlb
(n = 25)
Range n Rangec Converted 
mean
n Rangev Converted 
mean
Total bacterial count
Total bacterial count 11-12 28 9-12 10.32 25 - 10.55
Total aerobe count 7-8 28 5-9 7.35 25 - 9.92
Total anaerobe count 8-12 28 9-12 10.31 25 - 11.58
Candida < 4 18 0-6 3.49 - - 3.39
Facultative Gram negative bacteria
Escherichia coli 7-8 27 4-8 6.59 23 4-11 8.10
Klebsiella spp. <5 3 4-7 5.48 12 4-10 4.81
Citrobacter spp. <6 0 - - 1 8 2.76
Enterobacter spp. <6 4 5-7 6.24 1 4 2.17
Facultative Gram positive bacteria
Enterococcus spp. <6 9 6-7 6.41 - - -
Staphylococcus spp. <5 8 5-7 5.63 9 4-10 4.44
Streptococcus spp. <6 25 5-9 6.73 - - -
Alpha-haemolytic Streptococcus <6 14 4-8 6.66 9 5-11 3.91
Beta-haemolytic Streptococcus <6 5 4-6 5.17 - - -
Non-haemolytic Streptococcus <6 22 4-9 6.43 - - -
Anaerobic Gram negative bacteria
Bacteroides 8-12 27 9-11 9.93 10 - 9.63
Prevotella spp <10 19 9-11 9.73 - - -
Porphyromonas spp. <9 2 9-10 9.80 - - -
Eurobacterium <9 7 9-11 9.67 - - -
Anaerobic Gram positive bacteria
Eubacterium <9 0 - - - - -
Bifidobacterium spp. 7-9 22 7-10 9.29 10 - 8.31
Lactobacillus spp 6-8 8 7-10 8.24 10 - 6.90
Clostridium spp. <9 28 0-10 9.71 - - -
Peptostreptococcus spp. <5 1 0-10 9.71 - - 5.91
Note: aBioscreen (2009); bFinegold et al (1975); cLog10 no. of organisms per g of faeces (rounded off to nearest log in the case of range)
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Table 3 
Microbiological data from examination of faecal samples obtained from 10 selected children with abnormal microbiota 
compared with a control group
Microbiological data, by patient number
Organism isolated Control 
group 
converted 
meana,b
Patient 
1
Patient 
2
Patient 
3
Patient 
4
Patient 
5
Patient 
6
Patient 
7
Patient 
8
Patient 
9
Patient 
10
Total bacterial count 10.55 9.61 8.98 10.28 10.51 10.26 10.28 9.91 11.18 9.36 10.43
Total aerobe count 9.92 8.84 5.00 7.18 7.43 5.96 8.57 6.73 6.58 6.18 8.20
Total anaerobe count 11.58 9.58 8.98 10.28 10.51 10.26 10.28 9.91 11.18 9.36 10.43
Candida 3.39 6.08 . . . . . . 4.85 . 4.46
Escherichia coli 8.10 6.94 4.08 7.18 5.90 4.87 6.97 6.61 6.08 6.11 .
Klebsiella spp. 4.81 . . - 6.51 4.20 . . . . .
Enterococcus spp. - 7.11 . - . . . . 5.36 . .
Staphylococcus spp. 4.44 6.48 . - 5.20 . 5.57 . . . 4.88
Streptococcus spp. - 8.82 4.49 4.79 7.36 5.91 8.56 6.15 . 5.32 8.20
Bifidobacterium spp. 8.31 8.83 7.32 . 8.75 9.20 . 9.43 . 7.92 .
Lactobacillus spp. 6.90 7.83 . . - - 9.67 - - . 8.94
Clostridium spp - 4.61 6.79 9.96 9.90 4.61 5.82 9.15 10.23 6.49 9.83
Note: aFinegold et al (1975); bLog10 no. of organisms per g of faeces (rounded off to nearest log in the case of range)
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 Chapter 5 
Molecular characterization of gastrointestinal microbiota of children
with autism (with and without gastrointestinal dysfunction) and their
neurotypical siblings
The paper presented in the previous chapter (pilot study) 
(Gondalia et al., 2010a) suggested that the kind of individual aberrations 
found in the participants were consistent with the current consensus that 
GI dysfunction does occur more frequently in ASD than non-ASD 
children. However, the findings failed to support the hypothesis that the 
GI microbiota of individuals with autism was significantly different from 
neurotypically developing children. Nevertheless, these results did 
indicate that not all the autistic individuals had disrupted GI microbiota 
and that possibly only a minority of children with ASD showed evidence 
of GI microbial aberrations. 
The previous paper (pilot study) also suggested that limitations 
inherent in the study may, in part, explain the mixed findings. 
Specifically, the limitations of such research may be reduced with larger 
numbers of participants, related control (sibling) groups and by using 
high throughput bacterial analytical techniques rather than culture 
methods. Furthermore, the consistency of the results is potentially 
increased by comparisons based on the degree of severity and the GI 
dysfunctions.
The aim of the following paper, therefore, was to conduct 
experiments that overcame the limitations of previous studies. This study 
utilised advanced technology, namely bacterial tag encoded FLX 
amplicon pyrosequencing (bTEFAP), to explore the GI microbial 
community in faeces collected from autistic individuals and their 
neurotypical siblings. The technique enables testing of the bacterial 
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 community in a more comprehensive way and with a greater validity, in 
comparison to culture-based method.  
Participants were recruited across 4 groups; (1) children with 
autism with GI dysfunction, (2) children with autism without GI 
dysfunction, (3) neurotypical siblings with GI dysfunction and (4) 
neurotypical siblings without GI dysfunction. Children with autism and 
their neurotypical siblings were recruited for the detailed comparison of 
GI microbiota whilst keeping other variables, such as the surrounding 
environment, similar. Participants were excluded from the study if they 
were using any antibiotic/probiotic treatment 15 days prior to sample 
collection to remove any effect of antibiotics on resident GI microbiota.
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Molecular Characterisation of Gastrointestinal Microbiota of Children
With Autism (With and Without Gastrointestinal Dysfunction) and
Their Neurotypical Siblings
Shakuntla V. Gondalia, Enzo A. Palombo, Simon R. Knowles, Stephen B. Cox, Denny Meyer, and
David W. Austin
Many children with autism spectrum disorders (ASDs) suffer from gastrointestinal problems such as diarrhoea, consti-
pation and abdominal pain. This has stimulated investigations into possible abnormalities of intestinal microbiota in
autistic patients. Therefore, we designed this study to identify differences (and/or similarities) in the microbiota of
children with autism (without gastrointestinal dysfunction: n = 23; with gastrointestinal dysfunction: n = 28) and their
neurotypical siblings (n = 53) who share a similar environment using bacterial tag-encoded FLX amplicon pyrosequenc-
ing. Regardless of the diagnosis and sociodemographic characteristics, overall, Firmicutes (70%), Bacteroidetes (20%) and
Proteobacteria (4%) were the most dominant phyla in samples. Results did not indicate clinically meaningful differences
between groups. The data do not support the hypothesis that the gastrointestinal microbiota of children with ASD plays
a role in the symptomatology of ASD. Other explanations for the gastrointestinal dysfunction in this population should
be considered including elevated anxiety and self-restricted diets. Autism Res 2012, 5: 419–427. © 2012 International
Society for Autism Research, Wiley Periodicals, Inc.
Keywords: faecal microbiota; pyrosequencing; autism spectrum disorder; gastrointestinal dysfunction
Introduction
Autism spectrum disorders (ASDs) are deﬁned by cogni-
tive defects, impairments of spoken and/or receptive lan-
guage, social interactions, and repetitive and stereotyped
behaviours. In addition to these core deﬁcits, previous
studies indicate that the prevalence of gastrointestinal
(GI) symptoms is high in individuals with ASD [Buie
et al., 2010; Finegold et al., 2002; Gondalia, Palombo,
Knowles, & Austin, 2010a,b]. The percentage of individu-
als suffering from GI problems varies from study to study
[Buie et al., 2010], but high rates of GI dysfunction in
individuals with ASD have been reported in several
studies with symptoms including abdominal pain, con-
stipation, diarrhoea, diarrhoea and alternating constipa-
tion, and GI inﬂammation [Horvath, Papadimitriou,
Rabsztyn, Drachenberg, & Tildon, 1999; Levy et al., 2007,
Molloy & Manning-Courtney, 2003]. An elevated preva-
lence of GI dysfunction in individuals with autism was
ﬁrst reported by Goodwin, Goodwin, and Cowen [1971].
In a study of 137 children with ASD, 24% had a history of
at least one GI symptom. Another study found that 70%
of children with ASD presented with GI symptoms com-
pared with 28% of neurotypically developing children
and 42% of developmentally disabled children [Valicenti-
Mcdermott et al., 2006]. Additionally, in a metal toxicity
study of 51 children with ASD compared with 40 typical
controls aged 3–15, 63% of children with autism were
reported to have diarrhoea and/or constipation compared
with 2% of the control children [Adams, Holloway,
George, & Quig, 2006]. In summary, these studies consis-
tently demonstrate that GI symptoms are common in
ASD paediatric populations, although the precise nature
of these symptoms varies considerably both between and
within study populations.
GI dysfunctions, like diarrhoea, constipation and
abdominal pain, are unpleasant and may lead to frustra-
tion, decreased ability to concentrate, behavioural prob-
lems, and possibly aggression and self-abuse, especially in
children unable to communicate [Hollander & Anagnos-
tou, 2008], although there is little direct evidence for this.
The cause of GI dysfunction in the ASD population is
unclear, but it may partly relate to the use of oral antibi-
otics that can alter gut microbiota. Many studies have
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reported signiﬁcantly higher oral antibiotic use in chil-
dren with autism than typical children [Adams et al.,
2006; Adams, Romdalvik, Levine, & Hu, 2008; Konstan-
tareas & Homatidis, 1987; Niehus & Lord, 2006]. Further-
more, occurrence of ear infections and the use of
antibiotics were signiﬁcantly higher in children with ASD
than typically developing children [Niehus & Lord,
2006]. These antibiotics can disrupt the protective micro-
biota that plays an important role in normal GI function.
The disruption of this normal gut microbiota can create
favourable conditions for colonisation by pathogenic
and/or harmful bacteria, and it is hypothesised that this
can cause or contribute to GI dysfunction commonly
reported in ASD populations.
Bolte [1998] ﬁrst hypothesised a possible role for
Clostridium tetani in the pathophysiology of autism,
which was followed by many studies showing over-
growth of Clostridium species and other harmful bacteria
in ASD populations. Sandler et al. [2000] studied the
effects of a minimally absorbed oral antibiotic (vancomy-
cin) on 11 children with regressive-onset autism. This
treatment produced short-term improvement in autistic
symptoms using multiple pre- and post-therapy evalua-
tions. The same research team then studied the GI micro-
biota in 13 children with late-onset autism and eight
controls using conventional culture and polymerase
chain reaction (PCR) methods. Results indicated higher
counts of Clostridium and Ruminococcus species in autistic
children and a few species of these genera present only in
the faeces of children with autism [Finegold et al., 2002].
In a follow-up study, Song, Liu, and Finegold [2004] used
quantitative real-time PCR to evaluate Clostridium species
in the faeces of children with autism and controls. They
found that mean cell counts of Clostridium cluster groups
I and XI were signiﬁcantly higher in autistic children
than those of control children. Finegold et al. [2010]
investigated GI microbiota in 33 autistic children, 7 neu-
rotypical siblings and 8 nonsibling controls using the
bacterial tag-encoded FLX amplicon pyrosequencing
(bTEFAP) procedure. Study data indicated several differ-
ences at the phylum level, including higher levels of
Bacteroidetes in the severely autistic group and higher
levels of Firmicutes in the control group. Additionally,
Desulfovibrio species and Bacteroides vulgatus were present
in higher numbers in autistic than control children. Nev-
ertheless, this study did not show a signiﬁcant difference
between the autistic and neurotypical sibling control
groups. In a follow-up study, Finegold [2011] hypoth-
esised that Desulfovibrio may play a role in autistic symp-
tomology. This species produces important virulence
factors like lipopolysaccharides (LPSs) and hydrogen sul-
phide. Its unique physiology is congruent with some of
the pathophysiology seen in autism.
GI microbiota can produce toxic metabolites that can
gain access to the central nervous system (CNS) via the
vagus nerve. Some studies have reported increased intes-
tinal permeability that increases the absorption and pas-
sages of toxic metabolites. Studies of urinary biomarkers
for autism have reported elevated levels of p-cresol in
severely affected males [Altieri et al., 2011; Yap et al.,
2010]. P-cresol is a metabolically active toxic compound
produced primarily by Clostridia. Similarly, the bacterial
metabolic end-product, propionic acid [Shultz et al.,
2008], produces social impairment in experimental mice
when injected into the cerebrum.
In short, disruption of normal neurodevelopment by
GI microbiota and its metabolites has been theorised to
contribute to autistic pathology. We noted previously
that not all autistic individuals suffer from GI dysfunc-
tion and that only a subpopulation is affected [Gondalia
et al., 2010a]. Although numerous intestinal microbial
abnormalities have been identiﬁed in autism, conﬂicting
results have often been reported. The purpose of this
study was to identify whether a difference exists between
the resident GI microbiota in children with autism (with
and without GI dysfunction) and their neurotypical
siblings.
The intestinal microbial ecosystem is very complex,
and therefore, it is very difﬁcult to study the entire eco-
system using conventional microbiological methods like
culture methods. Nevertheless, researchers examining GI
microbial variables in ASD populations have most com-
monly used this method. Culture methods have many
limitations over nonculture (molecular) methods. For
example, some microorganisms are not able to grow in
culture media in laboratory conditions, and therefore, it
is very difﬁcult to conduct a comprehensive ecological
study. Newly developed molecular methods overcome
this limitation [Finegold, 2008, 2011; Finegold et al.,
2002, 2010; Song et al., 2004] and allow for the identiﬁ-
cation of a comprehensive range of microorganisms in
samples compared with culture methods by directly
extracting the DNA and then carrying out sequencing for
determining the speciﬁc bacterial composition. There-
fore, we used advance technology, bTEFAP, to study the
GI microbial community in the faeces of children with
autism and their neurotypical siblings.
Method
This publication reports on a study of children with
autism compared with their neurotypical siblings. The
study was approved by the Human Research Ethics Com-
mittee of Swinburne University of Technology, Australia.
Participant Recruitment
Participants were recruited through notices posted on
websites and newsletters of various local state and
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national bodies related to autism (Autism Victoria,
Autism South Australia, Autism Spectrum Australia and
Autism Australian Capital Territory, and autism schools
in Victoria (Wantirna Heights School, Southern Autistic
School, Western Autism School, Northern School for
Autism, and Mansﬁeld Autism Statewide Services) and
New South Wales (Aspect Central Coast School, Aspect
Hunter School, Aspect South Coast School, Aspect South
East Sydney School, Aspect Vern Barnett School and
Aspect Western Sydney School)).
Enrolment Criteria
1. Family having at least two children: one with autism
or Asperger’s disorder, and one neurotypical sibling,
aged 2–12 years.
2. No use of any type of antibiotic or antifungal at least
15 days prior to faecal sampling.
3. Autism group: formal diagnosis of autism/Asperger’s
by a psychiatrist or psychologist.
Protocol
1. The study was explained to parents, and informed
consent was received.
2. Parents ﬁlled out a questionnaire on their children’s
diagnosis and symptoms (including GI).
3. Stool samples were collected by parents in sterilised
faecal sample collection container during March–June
2011 and transported to Swinburne University in a
1-day express air post satchel containing a frozen gel
ice pack. In the laboratory, samples were thawed and
homogenised in sterile MilliQ water, and DNA was
extracted. The extracted DNA was stored at -20°C
until further analysis.
One hundred and four children (n = 51 with ASD and
n = 53 neurotypical siblings) with an age range of 2–12
years participated in this study (see Table I for participant
characteristics). The autism severity category was based
on Childhood Autism Rating Scale (CARS) assessments
[Rellini, Tortolani, Trillo, Carbone, & Montecchi, 2004]
conducted by registered psychiatrists or psychologists, as
reported by the parents of participants. Existing assess-
ments only were used; no conﬁrmatory assessment was
conducted. In Australia, formal assessment and reassess-
ment of autism and Asperger’s disorder occur annually as
part of the requirements of the educational and social
services systems. Therefore, we can assume that the
assessments were current to within 12 months. The GI
dysfunction criteria included one or more of the follow-
ing listed symptoms: constipation, diarrhoea, abdominal
discomfort or pain, gaseousness, and foul-smelling stools.
DNA Extraction
One-millilitre aliquots of stool, previously diluted 1:3 in
sterile MilliQ water, was thoroughly homogenised and
centrifuged at 13,000 ¥ g for 3 min to pellet faecal bacte-
rial cells. The supernatant was carefully removed and
discarded. Two hundred milligrams of cell pellet were
transferred to a fresh tube and subjected to DNA extrac-
tion using a commercial extraction system (QIAamp DNA
stool mini kit, Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. The concentration of
extracted DNA was measured by a nanodrop spectropho-
tometer (Biowave-II, Biochrom, Cambridge, England).
Massively Parallel bTEFAP
bTEFAP was performed, as described previously, using
Gray28F 5′TTTGATCNTGGCTCAG and Gray519r 5′ GT
NTTACNGCGGCKGCTG [Dowd, Callaway et al., 2008;
Dowd, Sun et al., 2008; Dowd, Wolcott et al., 2008; Ishak
et al., 2011; Sen et al., 2009]. Initial generation of the
sequencing library utilised a one-step PCR, with a total of
30 cycles, with a mixture of Hot Start and HotStar high-
ﬁdelity Taq polymerases. Tag-encoded FLX amplicon
pyrosequencing analyses utilised a Roche 454 FLX instru-
ment with titanium reagents (Roche, Nutley, New Jersey).
Titanium procedures were performed at the Research and
Table I. Summary of Participant Characteristics
Participant characteristic Subcategory
Autism
(n = 51)
Neurotypical
sibling
(n = 53)
Gender Male 42 19
Female 9 34
Age (years) All subjects 2–12 2–12
Severity Moderate–severe 21 NA
Mild 30 NA
Twins pair Identical 1 1
Current GI dysfunction,
n (%)
GI dysfunction 28 (55) 4 (8)
Constipation 12 (23.5) 3 (5.6)
Diarrhoea 5 (10) 1 (2)
Abdominal pain 7 (14) 2 (4)
Gaseousness 6 (12) 1 (2)
Foul-smelling stool 12 (23.5) 4 (7.5)
No GI dysfunction 23 (45) 49 (92)
Past history of GI
dysfunction
11 8
Medically diagnosed GI
disorder
All subjects 5 3
Current oral antibiotic All subjects 0 1
Current probiotics, n (%) All subjects 17 (33) 8 (15)
Feeding till the age of
6 months
Breastfeed 23 27
Formula feed 12 11
Both 15 15
Food allergy,a n (%) All subjects 21 (43) 4 (8)
Immunisationb Immunisation 50 47
No immunisation 1 6
aGluten-, casein-, dairy-, lactose- or preservative-free.
bAustralian standard immunisation schedule according to age.
GI, gastrointestinal; NA, Not Applicable.
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Testing Laboratory (RTL) (Lubbock, TX, USA) based upon
RTL protocols (http://www.researchandtesting.com).
Bacterial Diversity Data Analysis
Following sequencing, all failed sequence reads, low-
quality sequence ends, and tags and primers were
removed; sequence collections were depleted of any non-
bacterial ribosome sequences and chimeras using B2C2
[Gontcharova, Wolcott, Hollister, Gentry, & Dowd,
2010], as has been previously described [Dowd, Zaragoza,
Rodriguez, Oliver, & Payton, 2005]. To curate the data
short reads (<150 bp), sequences with ambiguous base
calls and sequences with homopolymers >6 bp were
removed. To determine the identity of bacteria in the
remaining sequences, sequences were denoised,
assembled into operational taxonomic unit (OTU) clus-
ters at 96.5% identity and queried using a distributed-
.NET algorithm that utilises Blastn+ (KrakenBLAST http://
www.krakenblast.com) against a database of high-quality
16S bacterial sequences. Using a .NET and C# analysis
pipeline, the resulting BLASTn+ outputs were compiled,
and data reduction analysis was performed, as described
previously [Dowd, Callaway et al., 2008; Dowd, Wolcott
et al., 2008; Wolcott, Gontcharova, Sun, & Dowd, 2009].
Bacterial Identiﬁcation
Based upon the earlier BLASTn+-derived sequence iden-
tity (percent of total length query sequence that aligns
with a given database sequence), the bacteria were clas-
siﬁed at the appropriate taxonomic levels based upon the
following criteria. Sequences identiﬁed to known or well-
characterised 16S sequences with identity scores greater
than 97% identity (<3% divergence) were resolved at the
species level between 95% and 97% at the genus level,
between 90% and 95% at the family level, between 85%
and 90% at the order level, between 80% and 85% at the
class level, and between 77% and 80% at phyla level.
After resolving based upon these parameters, the percent-
age of each bacterial identiﬁcation was individually
analysed for each sample, providing relative abundance
of information within and among the individual samples
based upon relative numbers of reads within each. Evalu-
ations presented at each taxonomic level, including per-
centage compilations, represent all sequences resolved to
their primary identiﬁcation or their closest relative
[Dowd, Callaway et al., 2008; Dowd, Sun et al., 2008;
Finegold et al., 2010; Ishak et al., 2011; Sen et al., 2009].
Principal Coordinates Analysis
Differences among microbial communities within groups
were characterised using the weighted Unifrac distance
[Lozupone & Knight, 2005]. Principal coordinates analy-
sis (PCoA) was then used to illustrate weighted Unifrac
distances in two dimensions. Weighted UniFrac is a
measure of community composition that takes into
account the proportion of bacteria found in each sample
[Fierer et al., 2010, Lozupone & Knight, 2007]. Multivari-
ate differences among groups were evaluated using
distance-based redundancy analysis (dbRDA). For the
dbRDA, distances among samples were ﬁrst calculated
using weighted UniFrac distances, and then an analysis of
variance (ANOVA)-like simulation was conducted to test
for group differences. UniFrac distances were calculated
using Quantitative Insights into Microbial Ecology
[Caporaso et al., 2010], and all other analyses were con-
ducted in R [Team, 2010] using the vegan [Jari Oksanen
et al., 2011] and labdsv [Roberts, 2010] packages.
Indicator species analysis [Dufrene & Legendre, 1997]
was used also to identify individual bacterial genera that
were indicative of each of the treatment groups. Indicator
species analysis synthesises information about occur-
rence and abundance of individual taxa, and this infor-
mation is summarised in an indicator score. The analysis
also provided a randomisation test of the degree to which
taxa are indicative of a particular state. First, genera that
were indicative of each of the levels of severity were
identiﬁed. Then, genera that were indicative of GI dys-
function were examined for autistic and neurotypical
samples separately.
Results
The numbers of species identiﬁed in a sample or the
numbers of organisms detected at any given phylogenetic
level are strongly affected by the number of sequences
analysed [Schloss & Handelsman, 2005]. Pyrosequencing
reads yielded an average of 4000 sequences >350 bp
(average length 450 bp) per sample after passing through
all quality controls and covered 19 phyla and 666 species.
At any phylogenetic level, it is necessary to model and
extrapolate the rarefaction curve or to use non-
parametric methods to estimate the true maximum value.
The non-parametric methods provide estimates that also
vary with sample size, so their approach to a richness
maximum must also be modelled and extrapolated. Dif-
ferences in OTU richness estimated via both raw richness
and Chao’s method (Fig. 1A,B) were assessed using
ANOVA. Both methods produce similar outcomes. The
ANOVA results obtained from these two methods are
F = 2,74, P = 0.071 for raw richness and F = 1.72,
P = 0.1865 for Chao’s method. Rarefaction and Chao’s
maximum predicted curve modelling indicated that 98%
OTUs at the 3% divergence were achieved for each
sample, which suggests adequate depth of coverage. To
make comparisons of richness, rarefaction was used to
standardise the number of sequences per samples at 2824.
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The average number of OTUs present in the faeces of all
autistic samples at 3% sequence divergence (the species
level) indicated no signiﬁcant difference between the
autistic and neurotypical sibling control groups.
Information at the phylum level was also analysed on
the basis of severity and GI dysfunction. The microbiome
mainly comprised 19 phyla overall. Of the major phyla,
Firmicutes, Bacteroidetes, Proteobacteria and Verrucomi-
crobia were the most abundant in all the samples. These
four phyla collectively constituted almost 99% of the
microbiome. All four phyla were consistently present in
all the groups (Fig. 2A,B). Firmicutes comprised 71%, 69%
and 72% of the bacteria in the severe autism, mild autism
and control groups, respectively. Figure 2A shows the
composition of autistic children and sibling controls with
and without GI dysfunction, respectively, emphasising
no difference between the autistic and control groups. We
also divided the group on the basis of the severity (severe
and mild) to check the microbiome composition (Fig. 2B)
and again showed no signiﬁcant difference within and
between the severity groups and controls.
Using the genus (301 genera) composition data to
analyse the microbiome further, differences among diag-
nosis groups in the overall microbiome were not signiﬁ-
cant (dbRDA P > 0.05). Furthermore, as can be seen in the
PCoA plot (Fig. 3), there was no systematic differences
among the three groups—severe, mild and control.
Regardless of the autism severity and GI dysfunction,
there was no clustering of samples, which again indicates
no signiﬁcant difference in the bacterial composition
within and between the autistic and control groups. Indi-
cator species analysis (Figs. 4 and 5) [Dufrene & Legendre,
1997] synthesises information about occurrence and
abundance of individual bacterial genera that is indica-
tive of each of the treatment groups, and this information
is summarised in an indicator score.
Discussion
The ﬁndings indicate that there was no signiﬁcant differ-
ence in the bacterial composition of faecal material of our
paediatric autistic group and their neurotypical siblings.
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Our data also indicated that there were no signiﬁcant
differences within the ASD group when comparing those
with and without GI dysfunction. The results, therefore,
are not consistent with several previous reports [Finegold,
2008; Finegold et al., 2002; Song et al., 2004].
Previous studies comparing autistic and control groups
have suggested that some microorganisms are more
related to autistic symptoms, as more species are found in
autistic cases than in neurotypical controls and those are
related to disease severity [Finegold et al., 2002]. It has
been hypothesised that Clostridium species are associated
with autistic symptomology and the spore-forming prop-
erty of Clostridia is of major importance for the reoccur-
rence of autistic symptoms after obtaining a good response
to oral vancomycin [Sandler et al., 2000]. This property
could also play a key role in the spread of bacteria to the GI
tract of siblings and playmates. However, in the recent
study by Finegold et al. [2010] using high-throughput
technology (pyrosequencing),Clostridiawere not found to
be particularly prevalent in the stools of autistic indi-
viduals, and there was a suggestion by the author that
Desulfovibrio might be important because it was more
common in autistic children than in controls. Further-
more, although not a spore-forming organism, Des-
ulfovibrio is very resistant to deleterious inﬂuences, and so
it is possible that it may play some role in recurrence of
autistic symptoms after treatment, although this needs to
be tested in future research. In another study, Bacteroidetes
were found at high levels in the severely affected autistic
children, whereas Firmicutes were more common in the
control children. They also indicated that siblings of autis-
tic children had more similar results to autistic children
than to the healthy controls. [Finegold et al., 2010]. Simi-
larly, Parracho, Bingham, Gibson, and Mccartney [2005]
reported intermediate levels of C. histolyticum group in
healthy siblings of autistic children, whichwas not signiﬁ-
cantly different from that of the autistic and healthy
control groups. Thus, these studies suggest little consis-
tency in the microbial proﬁle of autistic children, suggest-
ing that there are no particular bacteria clearly responsible
for the pathophysiology of autism.
It is possible, therefore, that the elevated rates of GI
dysfunction found in ASD populations might be based on
factors other than GI microbiota. For example, it is well
established that individuals with ASD have elevated
levels of anxiety and distress [Hutman et al., 2010; Mayes,
Calhoun, Murray, Ahuja, & Smith, 2011; Mayes,
Calhoun, Murray, & Zahid, 2011; Wood et al., 2009]. GI
research has highlighted the importance of the “gut–
brain axis,” especially in relation to depression and
irritable bowel syndrome, which is mainly focused on
“top-down” control, or the examination of the impact
that the brain can have on general gut function [Aziz &
Thompson, 1998]. New work involving GI symptoms in
anxiety and distress is indicating that stress and anxiety
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have an impact on GI function and condition. More
likely, GI symptoms appear as a signiﬁcant indicator for
the presence of depression and anxiety [Mussell et al.,
2008]. Using the top-down approach, research supports
the theory that early life stress will lead to altered stress
reactivity later in life and an altered gut microbial proﬁle
[O’mahony et al., 2009]. Therefore, it is possible that
psychological rather than physiological factors may
better account for the GI distress in the autistic indi-
vidual. Nevertheless, GI dysfunction, irrespective of a
psychological or physiological basis, is likely to cause
stress in the individual.
Overall, the results of the current study do not support
the hypothesis that the GI bacterial composition of chil-
dren with ASD (both with and without GI dysfunction) is
signiﬁcantly different from their neurotypical siblings.
This then further supports rejection of the hypothesis
that there may be a GI bacterial pathophysiological
mechanism triggering or maintaining ASD.
A particular strength of this study was that it compares
microbiota in autistic children with and without GI dys-
function and compares these children with their neuro-
typical siblings—again, with and without GI dysfunction.
Another strength was the large sample size and the
molecular characterisation of the bacterial population
extant in the faecal samples that included 666 different
bacterial species. Nonetheless, there are several important
limitations to this study that should be considered. First,
this study used a prior assessment of autism (via the
CARS) as a dependent variable and associated this to
currently reported GI dysfunction. Ideally, thorough vali-
dated current assessments such as the Autistic Disorder
Observational Schedule [Lord et al., 1989] would be con-
ducted; however, this was beyond the resources of the
present study. Furthermore, this study only evaluated the
bacterial community. Microbial species beyond bacteria
should ideally also be examined, including viruses, fungi
and protozoa. In addition, we did not control for dietary
differences among our participants, and as ASD children
typically have a self-limited diet, it would be better to
experimentally control dietary intake to remove its
impact on GI microbiology. Furthermore, future research
should focus on other microbial correlates to ASD rather
than just the composition of GI microbiota. Importantly,
microbial end-products/metabolites (i.e. neurotoxins,
phenolic compounds and LPS) should be investigated, as
these metabolites can be transmitted to the CNS and have
the ability to modulate its function. Of course, it is also
important to explore psychological factors such as
anxiety and distress in future research in order to clarify
their relationship with both GI function and autistic
symptomatology.
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 Chapter 6
Evaluation of biogenic amines in the faecal samples of children with
autism by LC-MS/MS
The findings of the papers presented in the previous chapters 
(Gondalia et al., 2010a; Gondalia et al., 2012) contribute significantly to 
the literature by confirming that GI dysfunction is more common in 
children with autism than typically developing control. However, the 
findings do not support the hypothesis that the GI microbiota are 
different and have a particular role in triggering or maintaining ASD. It is 
likely, therefore, that the higher rates of GI dysfunction found in ASD 
populations may be based on other factors.
Intestinal bacteria produce metabolites and release them into the 
surrounding environment as a result of host-microbial interactions and as 
part of their metabolic activities (Mishra et al., 2012). These metabolites 
can have significant effects on the host system. To date, very little 
research has been carried out to investigate the involvement of these 
metabolites in the pathophysiology of autism (MacFabe et al., 2011; Yap 
et al., 2010). 
Yap et al. (2010) investigated the urine metabolic profile of 
children with autism and matched controls and noted that certain 
bacterial metabolites, namely dimethylamine, hippurate and 
phenyacetylglutamine (PAG), were in significantly different amounts in 
the affected and control groups. This observation has been associated 
with disrupted GI microbiota. Depletion of hippurate and PAG are 
reported after the ingestion of antibiotics like vancomycin (Yap et al., 
2008) and gentamicin (Lenz et al., 2005).
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  Baker (1995) has reported that a significant percentage of 
individuals with autism have a history of extensive antibiotic use, 
supporting the observation that different amounts of bacterial metabolites 
reported in autism may have links with antibiotic use (Cryan et al., 2012; 
Parracho et al., 2005; Willing et al., 2011). Other bacterial metabolites 
that may relate to autism include short chain fatty acids (SCFA), biogenic 
amines (BA) and lipopolysaccharides (LPS) (Darlington et al., 2009; 
Kirsten et al., 2012; Wang et al., 2012).
The group of metabolites termed biogenic amines (BAs) includes 
cadaverine, putrescine, spermidine, histamine, agmatine, tryptamine, 
tyramine, serotonin, spermine and dopamine. These amines play a 
number of physiological roles in humans by acting as neurotransmitters 
(Medina et al., 2003). Research has indicated varied levels of these BAs 
in the blood and cerebrospinal fluids in individuals with autism 
(McCauley et al., 2004; Prasad et al., 2009). 
The concentrations of biogenic amines present in cells and tissues 
are strongly controlled. However, the ingestion of foods rich in BAs or 
their production in the intestine by intestinal microbiota can alter the 
equilibrium (Mah et al., 2002; Taylor et al., 1986). This may cause host 
responses which can play an etiologic role in various conditions. BAs 
have been associated with migraine, schizophrenia, colon cancer and the 
onset of hypertensive symptoms (Agostinelli et al., 2007; Bardocz, 1995; 
Issa et al., 1994; Jansen et al., 2003; Onal, 2007). However, an 
association between BAs, GI dysfunction and autism has not been made.
 The following study was therefore designed to quantitatively 
examine seven BAs, namely tryptamine, tyramine, histamine, 
spermidine, agmatine, cadaverine and putrescine, in the faeces of 
children with autism and their neurotypically developing siblings. A 
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 liquid chromatography mass spectrometry-based method was developed 
for the analysis of BAs in faecal samples.
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Abstract
Previous researchers have postulated that gastrointestinal bacteria may
contribute to the development and maintenance of Autism Spectrum Disorders
(ASD). There is evidence based on quantitative evaluation of the
gastrointestinal bacterial population in ASD that this is unlikely and an
alternate mechanism will be examined where the bacteria may contribute to
the development of ASD via their metabolic products and the role of biogenic
amines (BAs) will be investigated. In humans, BAs influence a number of
physiological processes via their actions as neurotransmitters, local hormones
and gastric acid secretion. Various amines have been implicated in several
medical conditions such as schizophrenia and colon cancer. To date, the
relationship between BAs and autism has not been explored. This study has
been designed to identify differences (and/or similarities) in the level of BAs
in faecal samples of autistic children (without gastrointestinal dysfunction: n =
14; with gastrointestinal dysfunction; n = 21) and their neurotypical siblings (n
= 35) by LC-MS/MS. Regardless of the diagnosis, severity of ASD and
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gastrointestinal dysfunction there were no significant differences found
between the groups. The findings suggest that BAs in the gastrointestinal tract
do not play a role in the pathophysiology of gastrointestinal dysfunction
associated with ASD.
Keywords: Autism, ASD, biogenic amines, faecal, chromatography.
Introduction
Biogenic amines (BAs) are low molecular weight nitrogenous compounds mainly
formed and degraded as part of the normal metabolism of animals, plants and
microorganisms by decarboxylation of amino acids or by amination and
transamination of aldehydes and ketones [1]. The basic structure of BAs can be
aromatic (tyramine, phenylethylamine), aliphatic (putrescine, cadaverine, spermine,
spermidine) or heterocyclic (histamine, tryptamine). In humans, BAs play a number
of physiological roles by acting as neurotransmitters and local hormones [2]. BAs are
involved in gastric acid secretion; cell growth and differentiation; they are required
for the synthesis of DNA, RNA, and proteins; are involved in the regulation of
circadian rhythm; maintenance of body temperature; food intake; learning and
memory; immune response and allergic reactions [3; 4; 5]. An essential factor in the
formation of BAs in food products and the gastrointestinal (GI) tract is the presence of
bacterial strains with the capacity to decarboxylate amino acids. This ability has been
described in different genera, species and strains of bacteria, both Gram positive and
Gram negative. Amino acid decarboxylases are found in certain Enterobacteriaceae,
Clostridium, Lactobacillus, Streptococcus, Micrococcus and Pseudomonas species,
among others [6].
The concentrations of BAs present in cells and tissues are strongly controlled at
the stages of catabolism, biosynthesis, uptake and efflux, however, the ingestion of
foods rich in BAs or production in the intestine by intestinal microbiota can alter the
equilibrium [7; 8]. Various BAs have been associated with migraine, schizophrenia,
colon cancer and the onset of hypertensive symptoms [4; 9; 10; 11; 12], however, a
link between BAs and Autism Spectrum Disorder (ASD) has not been explored
despite many researchers suggesting that gastrointestinal bacteria contribute to the
development of ASD [13; 14].
ASDs are defined by cognitive defects, impairments of spoken and/or receptive
language and social interactions as well as repetitive and stereotyped behaviours. In
addition to these core deficits, previous studies have indicated that the prevalence of
gastrointestinal distress is high in individuals with ASD [15; 16; 17; 18; 19]. The
percentage of individuals suffering from GI problems varies from study to study, but
high rates of GI dysfunction in individuals with ASD have been reported in several
studies with symptoms including abdominal pain, constipation, diarrhoea, alternating
diarrhoea and constipation as well as GI inflammation [20; 21; 22].
In a previous study, we noted that not all ASD individuals suffered from GI
dysfunction and that only a sub-population were affected. We also noted that only a
subset of this GI dysfunction group had unusual bacterial populations, which included
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very high and very low numbers of beneficial bacteria and similarly harmful bacteria,
regardless of severity and GI dysfunction [18]. In a subsequent study, we failed to
find any significant differences in the microbiome of ASD children (with and without
GI dysfunction) and their neurotypical siblings (with and without GI dysfunction)
[23], however, given that GI distress is a commonly reported symptom in ASD
children, we have designed this follow up study to consider other possible factors that
may contribute to GI dysfunction. Therefore, we evaluated BAs which can be
produced by microbiota [24] or ingested from food rich in BAs and directly absorbed
through the intestinal epithelium. High quantities of tyramine and histamine have
been associated with GI symptoms including nausea, abdominal cramping and
diarrhoea. Tyramine has been proposed as an initiator of hypertensive crisis [3]. The
toxicity of histamine appears to be enhanced by the presence of other amines such as
cadaverine, putrescine and tyramine. These biologically active amines have important
physiological effects in humans, generally either psychoactive or vasoactive [25]. All
have been shown to be involved in the central nervous system responses to stress [26].
BAs also act as releasing agents for the neurotransmitters and abnormally low
physiological concentrations often result in clinical depression, whereas abnormally
high concentrations have a strong correlation with schizophrenia [27; 28]. To date, no
research has evaluated the role of BAs in the GI symptoms of autistic children even
though there is good evidence those BAs can influence neurological processes.
Analytical methods for BAs in faecal samples involve high performance liquid
chromatography (HPLC). Most biogenic amines require derivatisation to be detected
by a UV-Visible or fluorescence detector in HPLC. Therefore, liquid
chromatography mass spectrometry (LC-MS) is extensively used for their direct
analysis. With LC-MS, the derivatisation step can be avoided and sample processing
time can be reduced which is important when a large number of samples are to be
analysed. However, LC-MS is often affected by matrix effects where both ion
enhancement and suppression have been observed with suggested strategies available
if they are apparent [2]. Therefore, the method development process needs to
investigate this possibility with faecal samples being a relatively unique matrix
compared to other biological matrices such as urine, blood and saliva.
In this study, we have developed a method for the detection of the seven biogenic
amines in faecal samples. In this method, amines were extracted with aqueous
trichloroacetic acid (TCA), separated by liquid chromatography and detection was
achieved by positive ionisation with a triple quadrupole mass spectrometer operating
in multiple-reaction monitoring (MRM) mode. This method was applied to a range of
faecal samples obtained to identify differences (and/or similarities) in the biogenic
amines in children with autism.
2. Experimental
2.1 Sample collection
The study was approved by the Human Research Ethics Committee of Swinburne
University of Technology, Australia. Participants were recruited through notices
posted on websites and newsletters of various local state and national bodies related to
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autism (Autism Victoria, Autism South Australia, Autism Spectrum Australia and
Autism Australian Capital Territory), autism schools in Victoria (Wantirna Heights
School, Southern Autistic School, Western Autism School, Northern School for
Autism, Mansfield Autism Statewide Services) and New South Wales (Aspect Central
Coast School, Aspect Hunter School, Aspect South Coast School, Aspect South East
Sydney School, Aspect Vern Barnett School and Aspect Western Sydney School).
2.2 Protocol
1. The study was explained to parents and informed consent received.
2. Parents filled out a questionnaire relating to socio-demographic variables and
their children’s diagnosis and symptoms (including GI).
3. Stool samples were collected by parents in sterilized faecal sample collection
containers during March -June 2011 and transported to Swinburne University
in a 1-day express air post satchel containing a frozen gel-iced pack.
Seventy children (n = 35 with ASD and n = 35 neurotypical siblings) with an age
range of 2 to 12 years participated in this study (see Table 1 for participant
characteristics). The autism severity category was based on CARS (Childhood Autism
Rating Scale) assessment conducted by registered psychiatrists or psychologists as
reported by the parents of participants. Existing assessments were used; with no
confirmatory assessment being conducted. In Australia, formal assessment and re-
assessment of Autism and Asperger’s disorder occurs annually as part of the
requirements of the educational and social services systems. Therefore, we can
assume that the assessments were current to within 12 months. The GI dysfunction
criteria included one or more of the following listed symptoms: constipation;
diarrhoea; abdominal discomfort or pain; gaseousness; foul-smelling stools.
2.3 Reagents and standards
Ultra-pure water from a Millipore Milli-Q system (Milford, MA, USA) was used for
the preparation of all the solutions. Trichloroacetic acid (TCA) (≥99%), cadaverine 
dihydrochloride (>99%), histamine dihydrochloride (>99%), spermidine
trihydrochloride (>99.5%), tryptamine hydrochloride (99%), tyramine hydrochloride
(99%), agmatine sulphate (≥97%), ammonium formate and formic acid (≥95%) were 
acquired from Sigma–Aldrich, whereas acetonitrile was obtained from Merck.
A 30mM ammonium formate buffer (pH 4) was prepared and the pH was adjusted
with formic acid. Standard solutions of biogenic amines were prepared in Milli-Q
water and kept in 2 mL aliquots in plastic vials at −20°C. When required, these were
brought to 25°C before preparation of more diluted solutions in 2% TCA each day. A
fresh standard mixture of all seven amines (1 mg/mL) was prepared and further
diluted for calibration.
2.4 Extraction of biogenic amines
Two millilitres of 10% TCA was added to 1 g of faecal matter that was contained in a
15 mL Falcon tube. The mixture was homogenized by vortex mixing for 1 min, 8 mL
of Milli-Q water was added and the mixture was incubated for 30 mins at 4°C. The
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mixture was filtered through a Whatman no. 1 filter paper using a vacuum system.
The extraction process was carried out on ice to minimise the loss of the more volatile
amines. The filter was washed three times by adding 5 mL of 2% TCA each time and
the final volume was adjusted to 25 mL with 2% TCA. This solution was filtered
through a 0.45 μm nylon syringe filter and stored at −20°C until required for analysis.
2.5 Analysis conditions
Analyses were performed with an Agilent 6410 Triple Quadrupole LC/MS system
(Agilent Technologies Inc.). Chromatographic separation was developed on a Luna®
5 μm NH2 100 Å (250×3.0 mm) (Phenomenex, NSW, Australia). Isocratic elution
with 30mM ammonium formate adjusted to pH 4 with formic acid and acetonitrile in
a ratio of 3:1 was used with a flow rate of 0.5 mL/min and the injection volume was
50 μL. Quantitation of the amines was based on the fragmentation transitions MRM 
mode as listed in Table 2. The ESI probe tip was 3.5 kV, nitrogen was used as the
nebulizer gas and heated to 300°C at 15 psi, and the insource fragmenting voltage was
35 V for putrescine and 70 V for the other amines.
2.6 Statistical analysis
A one-way ANOVA and independent sample t-test were conducted to compare
amines between the groups based on ASD severity and GI dysfunction. Statistical
significance was defined as a p value of less than 0.05 with BA concentration data
presented as means with standard deviations. In addition, Principal Component
Analysis (PCA) was performed to further explore if there were any influential factors.
All statistical analyses were performed using Statistical Package for Social Sciences
(SPSS) for Windows Statistical Package Version 19.0.
3. Method validations
3.1 Linearity
The linearity of the method for each amine was determined from data collected for six
different concentrations of biogenic amines in mixtures ranging from 0.05 - 10 mg/L,
using triplicate injections for each mixture of different concentrations. Calibration
graphs for each amine were constructed by plotting the peak-area against the amine
concentration and the correlation coefficient is listed in Table 2. The correlation
coefficients indicate that good linearity exists for the range of concentrations tested,
which is also given in Table 2.
3.2 Limits of detection and quantification
The limits of detection (LOD) were calculated from the concentration of amines
required to give a signal-to-noise ratio of 3. The limits of quantification (LOQ) were
determined with a signal-to-noise ratio of 10. Both LOD and LOQ are presented in
Table 2.
3.3 Matrix effect
To study the effect of the matrix, 10 mL of faecal extract from the extraction
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procedure described in section 2.4 was spiked with a known amount of standard
mixture of amines. The faecal extract contained some amines and the areas for the
spiked samples were corrected by subtraction (the results of this analysis were
compared with a set of external standard mixtures using a four-point calibration curve
- 0.5, 1, 2.5, 5 μg/mL prepared in the 2% TCA). Matrix effect (ME) values were 
calculated according to the following formula [29].
%100x1⎟⎠
⎞⎜⎝
⎛ −=
A
BME (1)
Where, A is the peak area for the external standards and B is the peak area from the
spiked faecal samples. The values in Table 2 indicate that significant and varied ion
suppression prevents the use the external standards as prepared in section 2.3 and that
standardisation requires the use of standards prepared using spiked faecal samples.
3.4 Recovery
The overall recovery of the sample preparation process as described in section 2.4 was
determined by spiking 1 g of faecal sample with a known amount of standard mixture
of seven amines in three replicates. Once again the amount of amines initially present
was subtracted from the spiked samples. It can be seen from Table 2 that the recovery
of amines from the extraction process is quantitative but considering the matrix
effects previously described, it has not totally eliminated components from the faeces
that influence the ionisation process for the amines. However, the quantitative
recovery indicates that linearity is maintained in the sample matrix and
standardisation is possible using standards prepared in the faecal matrix.
Consequently single point standardisation (2 μg/mL) was used for the samples. 
3.5 Final Protocol
The final optimised method was as follows: Sample prepared as specified in section
2.4 and were analysed under condition described in section 2.5. The concentration of
the each compound was calculated based on single point standard (2 μg/mL) prepared 
in the faecal matrix.
Results and discussion
Participants were divided into two groups: those with moderate to severe ASD (n =
19) and those with mild ASD (n = 16) (Table 1). The severity category was based on
CARS assessments conducted by registered psychiatrists or psychologists and the
child’s score reported by parents of participants. CARS scores of less than 37 are
considered mild and those at or above 37 are considered moderate – severe [30].
Details of the specific amine concentrations are given in Table 3 with all
concentrations being based on the weight of the wet faecal sample. Analyses of
variance revealed no significant differences between the ASD severity groups and the
sibling controls on mean levels of all analytes (Table 3). Furthermore, no relationships
for the biogenic amines were evident between the GI dysfunction and GI normal
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group (Table 4). However, PCA reveals correlation between GI dysfunction and
severity (correlation coefficient 0.578). In autism group, 39% of participants with
severe autism and 61% with mild autism suffered from GI dysfunctions compare to
2.8% in sibling control participants. Similar to ANOVA, no correlation was found
between any of the biogenic amines, autism severity and GI dysfunctions. However,
interestingly there was a correlation between histamine and cadaverine (correlation
coefficient 0.807). It has been observed that the presence of cadaverine potentiates
the biological activity of histamine in laboratory animals [31] most likely due to
increasing the histamine transport across the gastrointestinal wall [32; 33].
Several researchers have hypothesized that the numbers and the species of several
GI bacteria such as the Clostridium group, Ruminococcus and Deslufovibrio may
contribute to the development of ASD [13; 14; 34]. However, this hypothesis has little
consistency with other studies suggesting no significant difference in the bacterial
count in the autistic individuals and their neurotypical siblings [13; 17; 23; 35]. By
contrast, this study was designed to evaluate the level of BAs in autistic children and
determine whether BAs have any possible role in the GI dysfunction associated with
autistic disorder. The comparison of BAs in autistic children, with and without GI
dysfunction, and comparison of these children with their neurotypical siblings (again,
with and without GI dysfunction) did not reveal any significant differences, which
suggest that BAs in the GI tract may not play a significant role in the pathophysiology
of GI dysfunction associated with ASD. This follow-up study is consistent with our
previous study which did not support the hypothesis of a GI bacterial
pathophysiological mechanism triggering or maintaining ASD [23] as there were no
significant differences in the bacterial composition of faecal material of our paediatric
autistic group and their neurotypical siblings.
Table 1 Summary of participant’s characteristic
Participant characteristic Subcategory Autism
(n=35)
Neurotypical
sibling
(n=35)
Gender Male 28 10
Female 7 25
Age (years) All subjects 2-12 2-12
Severity Moderate-Severe 22 NA
Mild 13 NA
Current GI dysfunction, GI dysfunction 21 2
Constipation 9 2
Diarrhoea 4 0
Abdominal Pain 3 0
Gaseousness 5 1
Foul-smelling stool 9 2
No GI dysfunction 14 33
Past history of GI dysfunction 7 7
Medically diagnosed GI disorder All subjects 5 2
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Current oral antibiotic All subjects 0 0
Current probiotics All subjects 12 4
Other supplements Fish oil 9 5
Multivitamins 10 8
Laxative 2 0
Food allergy1 All subjects 15 4
Immunization2 Immunization 35 31
1Gluten, casein, dairy, lactose or preservative free. NA, not available.
2Australian standard immunization schedule according to age.
Table 2 Method validation values of biogenic amines for LC-MS/MS
Biogenic
amine
Fragmentation
transitions (m/z)
LOD
(μg/L)
LOQ
(μg/L)
Linearity
(mg/L)
R2 ME
(%)
Recovery
(%)
Spermidine 146.2 to 72.2 20 50 0.02-5 0.9966 -25±4 97±3
Tryptamine 144.0 to 117.2 25 85 0.025-5 0.9956 -30±3 94±1
Tyramine 138.1 to 121.1 20 50 0.02-5 0.9992 -24±4 98±8
Agmatine 131.1 to 114.1 30 100 0.03-5 0.9965 -17±5 105±14
Histamine 112.1 to 95.0 50 150 0.05-2.5 0.9997 -11±3 105±10
Cadaverine 103.2 to 86.2 500 1500 0.5-5 0.9947 -28±1 100±2
Putrescine 89.2 to 72.2 500 1500 0.5-2.5 0.9972 -30±3 100±8
Table 3 Mean values of biogenic amines (mg) examined per gram of faecal sample
for different groups (mild and severe) of ASD individuals and sibling controlwith the
associated ANOVA based p-value.
Biogenic Amines Control (n=35) Mild (n=16) Severe (n=19) p-value
Mean Std. dev Mean Std. dev Mean Std. dev
Spermidine 4.11 1.94 3.64 2.23 4.48 1.79 .463
Tryptamine 0.16 0.44 0.04 0.16 0.16 0.44 .269
Tyramine 0.09 0.21 0.18 0.61 0.31 0.69 .282
Agmatine 2.45 6.65 1.08 2.34 1.37 1.58 .588
Histamine 0.04 0.13 0.06 0.25 0.15 0.56 .516
Cadaverine 2.46 3.03 1.87 2.12 4.29 7.35 .236
Putrescine 5.41 7.24 4.84 8.29 3.96 4.62 .761
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Table 4 Mean values of biogenic amines (mg) examined per gram of faecal sample
for different groups (GI dysfunction and No GI dysfunction) of ASD individuals with
the associated ANOVA based p-value.
Biogenic Amines Autism (n=35) p-value
GI dysfunction (n=21) No GI dysfunction (n=14)
Mean Std. dev Mean Std.dev
Spermidine 3.88 1.97 4.44 2.11 .428
Tryptamine 0.10 0.38 0.10 0.26 .990
Tyramine 0.16 0.38 0.41 0.91 .271
Agmatine 1.15 1.47 1.39 2.55 .728
Histamine 0.18 0.58 0.00 0.00 .257
Cadavarine 4.37 7.03 1.40 1.43 .131
Putrescine 3.76 6.08 5.27 7.14 .505
Conclusions
We have demonstrated that the LC-MS/MS analysis technique can be used with direct
sample extraction and this decreases the sample processing time, which is desirable
for BAs analysis as they are very unstable. Furthermore, the reproducibility of the
analytical results is greatly improved due to automation. The recommended technique
can be easily integrated into future research assessing BAs in clinical samples
amongst a larger sample size.
The findings of our present study revealed no significant differences between the
ASD severity groups and the sibling controls. Furthermore, no relationships were
evident between the GI dysfunction and GI normal group. Therefore, this suggests
that BAs may not play a significant role in the pathophysiology of ASD.
Nevertheless, further research is warranted to investigate BAs in the other body fluids
and tissues before the role of BAs in ASD is ruled out.
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 Chapter 7: General Discussion 
This thesis used a variety of methodologies to explore the 
microbial profile of autistic children, including conventional 
microbiological culture methods, bacterial tag encoded FLX amplicon 
pyrosequencing (bTEFAP) to examine a comprehensive range of 
bacterial species (666 species), and bacterial metabolite investigation. 
The findings of this thesis go some way towards answering questions 
regarding the GI microbial profile of autistic children and neurotypically 
developing children.
The pilot study in Chapter 4 (Gondalia et al., 2010a) did not find 
any within-group differences in the GI microbial profile of an  ASD 
group when compared across clinical severity and gender. Furthermore, 
there were no significant differences found when compared to 
standardised laboratory reference ranges. Therefore, we hypothesised that 
not all children with autism have an abnormal GI microbial profile and 
that perhaps only a subset of individuals have disrupted GI microbiota.
 The findings of the pilot study described in Chapter 4 (Gondalia 
et al., 2010a) was further supported by a subsequent study (Gondalia et 
al., 2012) (Chapter 5) conducted on a larger sample size (n = 104). This 
study used a superior experimental design than previous studies, with 
participants being children with ASD and their non-clinical (typically 
developing) siblings. It utilised a high-throughput technique for 
identification of a comprehensive range of GI bacterial populations. The 
results of the study did not provide any evidence for differences in the GI 
bacterial profile between the autistic group and the neurotypical sibling 
group, therefore, the results do not support the hypothesis of such a 
difference proposed by some other researchers (Finegold et al., 2010; 
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 Finegold et al., 2002; Sandler et al., 2000; Song et al., 2004) that 
disruption of the gut microbiota, overgrowth of some pathogenic bacteria 
or suppression of beneficial bacteria play major roles in the development 
and/or maintenance of autism and related conditions. 
Some researchers have gone so far as to suggest that atypical 
microbial populations may actively contribute to autism symptoms. For 
example, research has shown that the metabolite propionic acid, a short 
chain fatty acid produced by gut bacteria, can alter the brain and 
behaviour (Finegold, 2008; MacFabe et al., 2011). Likewise, some other 
bacterial metabolites, such as LPS and amines, are also believed to 
interfere with normal physiological and psychological functions 
(Darlington et al., 2009; Jyonouchi et al., 2005). This thesis examined 
this latter hypothesis by evaluating the levels of a group of GI bacterial 
metabolites, biogenic amines (which act as neurotransmitters), in an 
autistic group compared to a neurotypical sibling group. The findings of 
this work concord with the previous two microbial study findings of this 
thesis in that, overall, the autistic group showed no significant differences 
in concentrations of biogenic amines to the typically developing sibling 
group. These results, therefore, suggest that these metabolites are 
unlikely to be playing a role in the GI dysfunction associated with 
autism. Nevertheless, it is too early to discount completely a connection 
between biogenic amines and autism. 
The findings of the thesis did not show any differences in 
microbial distribution and selected metabolites between children with 
autism and their neurotypically developing siblings when compared 
based on clinical severity and GI dysfunction. This indicates the 
possibility that the elevated rates of GI dysfunction found in ASD 
populations might be based on factors other than GI microbiota. 
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 It is well established that individuals with ASD have elevated 
levels of anxiety and distress (Hutman et al., 2010; Mayes et al., 2011a; 
Mayes et al., 2011b; Wood et al., 2009). GI research has highlighted the 
importance of the “gut–brain axis,” especially in relation to depression 
and irritable bowel syndrome (IBS) based on examination of the impact 
that the brain can have on general gut function (Aziz et al., 1998). New 
research involving GI symptoms in anxiety and distress is indicating that 
stress and anxiety have an impact on GI function and condition. More 
likely, GI symptoms appear as a significant indicator for the presence of 
depression and anxiety (Mussell et al., 2008). 
There are several mechanisms by which stress can affect the GI 
system and alter the bacterial composition, including changes in 
epithelial cell function, mucus secretion and GI motility (Ghia et al., 
2008; Varghese et al., 2006). Research supports the theory that early life 
stress will lead to altered stress reactivity later in life and an altered GI 
microbial profile (O'Mahony et al., 2009). The changes in the microbiota 
induced by infection, antibiotics or other events such as stress may have 
caused physiologic inflammation and perturbed GI physiology at the time 
of early life development. A change in GI physiology provides an altered 
habitat that in turn supports a different microbiota and this might have 
influenced the brain and behaviour. 
Animal studies have demonstrated that adverse early life events 
are associated with a maladaptive stress response system and might 
increase the vulnerability to disease in adulthood (Ackerman et al., 1978; 
O'Mahony et al., 2009). In a study by O’Mahony et al.,  a maternally 
separated and non-separated rat model was used to identify the response 
against stress by examining endocrine and immune measurements, whole 
blood stimulation and GI microbiota composition. The results indicated 
significantly higher concentration of cytokine – TNF-α (inflammation 
measure) and corticosterone (regulate physiological processes, 
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 inflammation and behavior). Perturbations in GI microbiota also have 
been observed. Together, these results indicate that early psychological 
factors induce physiological changes. Many other studies conducted on 
animal model have demonstrated that early life stress (i.e. maternal 
deprivation) can modify adult immune and gastrointestinal tract functions 
(Barreau et al., 2004; Overmier et al., 1997; Spencer et al., 2006). Stress 
can triggered a significant increase in colonic permeability, alter mucosal 
mast cell density and significantly higher inflammatory reaction.     
Therefore, it is possible that psychological, rather than 
physiological, factors may explain much of the GI distress in autistic 
individuals. Nevertheless, GI dysfunction, irrespective of a psychological 
or physiological basis, is very likely to be causal of stress in individuals. 
Additionally, it is very difficult for many children to maintain a proper 
diet and hygiene. Therefore, such children may be more likely to acquire 
intestinal infections compared to normally developing children. A 
restricted diet may also eventually result in other GI dysfunctions. 
Although the possible mechanisms are unknown, it has long been 
suggested that some intestinal lesions that increase intestinal permeability 
to exogenous peptides of dietary origin may lead to the disruption of 
neuroregulatory mechanisms and normal brain development 
(enterocolonic encephalopathy) (Wakefield et al., 2002). 
However, there are varied theories of the GI dysfunction 
associated with autism, therefore, clinically, it is necessary to evaluate 
each individual with autism based on the symptoms described by 
parents/guardian/doctors for possible intervention and treatment of GI 
dysfunction and the underlying autistic condition. A central difficulty in 
recognising and characterising GI dysfunction in ASD is the 
communication difficulties of many affected individuals. Thus, GI 
problems in individuals with ASD can be challenging to evaluate. 
Clinical practice guidelines exist for the evaluation and management of 
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 ASD by primary carers and other physicians but do not include routine 
consideration of potential GI and other medical problems. Nevertheless, 
some anecdotal evidence indicates that antibiotics, probiotics, special diet 
supplements or some restricted diets (e.g. gluten/casein free diet) can be 
used to successfully treat patients. Because of markedly differing 
presentations of autism conditions and associated GI dysfunctions, it is 
challenging to scientifically evaluate these interventions.
The American Academy of Paediatrics reported criteria for the 
diagnostic evaluation of GI symptoms and disorders in individuals with 
ASD (Buie et al., 2010). According to this report, GI symptoms are 
related to sleep disturbance associated with gastrointestinal reflux disease 
(GERD), self-injurious behaviour, tantrums, aggression, oppositional 
behaviour with constipation,  gastritis, intestinal inflammation, chronic 
diarrhoea with malabsorption and maldigestion, perceived abdominal 
discomfort, holding abdomen and crying, problem behaviours related to 
constipation,  lactose intolerance and enteric infections. These symptoms 
and associated possible GI conditions lead to possible diagnostic tests 
such as stool analysis for occult blood, enteric pathogens, ova/parasites, 
Clostridium difficile infection, abdominal radiograph, lactose breath test, 
colonoscopy and diagnostic trial of proton-pump inhibitors. 
GI conditions associated with autism have often been 
hypothesised as being linked to GI microbiota disruption and infections. 
Many researchers have suggested the treatment of GI dysfunction in ASD 
with anti- or pre/probiotics as a way to regulate intestinal microbiota and 
subsequently improve symptom severity in ASD (Sandler et al., 2000; 
Tuohy et al., 2003). However, it is challenging to accept these 
interventions for all autistic individuals because of wide variations in 
patient presentations and the lack of consistency and reproducibility in 
the research findings examining the involvement of GI microbiota in 
autism. 
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 In conclusion, the program of research reported here found no 
specific bacterial species or associated metabolites (amines) that reliably 
differentiated between children with autism and their neurotypical 
siblings. Therefore, it would appear that if gastrointestinal microbiota are 
involved in the etiology of ASD, it may only be evident at the time of 
commencement of the original pathogenesis of autism. Therefore, 
looking at microbiota years after diagnosis of autism may be too late. 
Furthermore, the results of this thesis do not provide evidence of 
involvement of microbiota in ASD severity, which may indicate that GI 
microbiota are not a relevant variable in maintenance mechanisms in 
autism. Nevertheless, it appears important clinically, that each ASD child 
be thoroughly assessed and cared for on an individualised basis in terms 
of both their ASD and any reported or identified GI distress. 
Limitations
The studies described in this thesis have some limitations which 
were difficult to avoid or overcome. These would have had some effect 
on the assessment and analysis of the indigenous microbial and 
metabolite profile of each individual.
Each individual has a different diet (non-controlled) which would 
likely have influenced the composition of the GI microbiota. The diet not 
only dictates the available nutrients for the microbiota but also helps to 
establish predictable and competitive relationships between intestinal 
bacteria. However, dietary differences were not controlled in the 
participants of the studies reported in this thesis. Given that ASD children 
typically have a self-limited diet, it would be scientifically better to 
experimentally control dietary intake to remove its impact on GI 
microbiology. More generally, the microbial profile of each individual is 
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 very different depending on lifestyle, personal hygiene and eating habits. 
Therefore, it is difficult to define a “typical” profile of microbiota for 
healthy individuals and, perhaps even more so, for individuals with ASD.
As with any other culture independent method, pyrosequencing 
has its limitations. The short length of reads generated by pyrosequencing 
may represent a limitation when bacterial identification is intended 
(Siqueira Jr et al., 2012). However, a pyrosequencing approach provides 
richer descriptive information about microbiota than any other molecular 
method of bacterial identification in terms of taxonomic levels and 
relative abundance values.
For the autistic and control groups, GI symptoms were measured 
by parental report only. No further evaluation was carried out by medical 
professionals. Furthermore, prior assessment of autism (via the childhood 
autism rating scale, CARS) was used as a dependent variable and this 
was associated with currently reported GI dysfunction. Ideally, thorough 
validated current assessments such as the autistic disorder observational 
schedule (ADOS) would be conducted; however, this was beyond the 
resources of the research program. Nevertheless, in Australia, formal 
assessment and re-assessment of autism and Asperger’s disorder occurs 
annually as a part of the requirements of the educational and social 
services systems. Therefore, it can be assumed that the assessments were 
current to within 12 months.
Suggestions for future research
In this thesis, the main focus was on bacteria and selected 
bacterial metabolites (biogenic amines) and their possible association 
with autism severity and associated GI dysfunctions. In order to advance 
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 our understanding of the role and cause of GI dysfunction in autism, 
other factors need to be evaluated in future research.
Microbial species beyond bacteria should also be examined, 
including fungi, parasites and protozoa. It is hypothesised that 
overgrowth of Candida in the intestine might occur secondary to 
antibiotic use or ingestion of processed sugar and other foods which 
enhance yeast growth  (Levy et al., 2005).  Also, little research has been 
conducted evaluating GI parasites and protozoa associated with autism 
and, yet, research has reported that the abnormalities in behaviour and 
clinical features associated with autism resemble those of chronic latent 
toxoplasmosis in humans and rodents (Prandota, 2010) caused by 
Toxoplasma gondii infections. 
It has also been reported that viral infections can trigger 
autoimmune responses and eventually lead to organ-specific autoimmune 
disease. With regards to the cause of autism, the trigger mechanism is not 
known but viral infections such as rubella, measles, human herpes virus-
6, influenza and cytomegaloviruses have been suspected (Brambilla et 
al., 2003; Hallmayer et al., 2011; Rosenberg et al., 2009; Sparks et al., 
2002). More through research is warranted to evaluate this possible 
mechanism where viral infection in early development may lead to 
autism.
Lipopolysaccharide (LPS) is localised to the exterior leaflet of the 
outer membrane of Gram-negative bacteria and serves as the major 
surface component of the bacterial cell envelope. It has been 
hypothesised that LPS can damage the blood brain barrier and induces 
the release of nitric oxide (neurotoxic) which is a gaseous 
neurotransmitter that diffuses in to the brain.  Furthermore, LPS toxicity 
works synergistically with mercury (and possibly other heavy metals) to 
expand the damage (Minami et al., 1998). In addition, LPS decreases 
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 glutathione levels, making it even more difficult for the body to excrete 
heavy metals (Zhu et al., 2007). The mechanisms by which LPS may 
play a role in autism are varied and may differ across subsets of autistic 
patients. Therefore, careful assessment is needed to identify the role, if 
any, of LPS in autism symptomatology, cognitive function and 
neurodevelopmental process.
Identifying an underlying association between infection with a 
microbial agent and a specific brain disease can be complex. In some 
cases, for example, herpes simplex encephalitis, the virus destroys 
infected brain tissue through replication. Immune responses to microbial 
agents can also lead to breakdown of tolerance to host antigens and result 
in tissue damage (Lipkin et al., 2008). The original infection may have 
been peripheral, as it is anticipated for tic disorder and obsessive 
compulsive disorder following streptococcal infection (Murphy M, 
2002). Another mechanism for psychological disorder is persistent non-
cytopathic viral infection (Pearce, 2003). Such infections can profoundly 
impact neurotransmitter function or brain development, yet remain 
unknown. Therefor it is necessary to study autoimmune responses to 
microbiological abnormalities in individuals with ASD.
Psychological factors such as anxiety and distress have to be 
evaluated in future research in order to clarify their relationship with both 
GI function and autistic symptomatology. Digestive system disorders, 
such as IBS, are often associated with affective disorders, such as 
depression, anxiety, panic and post-traumatic stress disorder (PTSD). 
Some of these associations are observed not only in clinical populations, 
but also in population-based samples, suggesting a relationship with 
pathophysiological mechanisms underlying both GI dysfunction and 
certain affective disorders. Continuous and severe life-threatening 
stressors can play an important role in the onset and modulation of GI 
symptoms as well as in the development of affective disorders and 
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 PTSD. A neurobiological research model is needed to better explain such 
an underlying association of functional GI disorders with anxiety and 
distress. 
The possible interactions between microbial factors in ASD with 
other proposed aetiological factors such as mercury poisoning, metabolic 
relationships and genetic foundations are other factors to consider in 
future research. Higher rates of autism diagnosis have led to hypotheses 
among researchers that environmental factors operate in concert with 
genetic risk factors in causing this developmental disorder. Autistic 
children exhibit evidence of oxidative stress and impairment in some 
metabolic functions, such as methylation and energy metabolism, which 
may reflect effects of toxic exposure on metabolism. It has been 
hypothesised that bacterial products and metabolites like LPS work 
synergistically with toxins like mercury and other heavy metals to 
expand the damage. The possible interactions between ‘competing’ 
hypotheses warrant attention.
The treatment of children with ASD is complex and time-
intensive. Because the of the elevated levels of GI distress in this 
population, treatments targeting the GI tract such as restricted diets (e.g., 
gluten- or casein-free diets) and use of supplements have been adopted to 
decrease the frequency of symptoms or to regulate GI functions. Further 
research is needed to (1) describe the relationship between nutritional 
intake and GI symptoms, (2) determine nutritional risk factors for 
children with ASD and selective diets, and (3) determine the etiology of 
GI dysfunction in children with ASD.
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 Summary
Overall, the series of studies reported in this thesis found no 
evidence to support the hypothesis that disruptions of the GI microbiota, 
overgrowth of some pathogenic bacteria or suppression of beneficial 
bacteria play a major role in the development of autism. This was 
supported by the findings of all three studies conducted based on culture 
methods, genetic analysis and metabolite investigation.
Nevertheless, we know children with ASD have increased GI 
disturbance than typically developing children. Therefore, it is critical for 
researchers to continue to explore possible mechanisms of this 
phenomenon. Given GI problems are associated with behavioural 
problems in ASD children, finding reasons for these GI problems (and 
their effective treatment) would be an enormous advance in the clinical 
management of this condition.
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Ethics approval from Swinburne University of Technology 
research committee for study entitled ‘faecal microbiota of individuals 
with autism spectrum disorder’ (Chapter 4).  
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To: Assoc Prof David Austin/Ms Shakuntla Gondalia, FLSS
Dear David and Shakuntla
SUHREC Project 2008/114 Autism and the Human Gut 
Microbiota Dr David Austin, FLSS; Ms Shakuntla Gondalia et al 
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Investigator May 2009]
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Swinburne's Human Research Ethics Committee (SUHREC). Your 
responses to the review were as emailed on 22 May 2009 with 
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and with respect to secure data use, retention and disposal.
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 Appendix B
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gastrointestinal microbiota of children with autism (with and without 
gastrointestinal dysfunction) and their neurotypical siblings’ (Chapter 5).  
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review by or on behalf of SUHREC. Amendments to approved 
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